A role of efflux pumps in intrinsic drug resistance and virulence of Mycobacterium tuberculosis by Villellas Arilla, María Cristina & Aínsa Claver, José Antonio
2013 75
María Cristina Villellas Arilla
A role of efflux pumps in intrinsic
drug resistance and virulence of
Mycobacterium tuberculosis
Director/es
Departamento
Bioquímica y Biología Molecular y Celular
Aínsa Claver, José Antonio 
Director/es
Tesis Doctoral
Autor
Repositorio de la Universidad de Zaragoza – Zaguan http://zaguan.unizar.es
UNIVERSIDAD DE ZARAGOZA
Departamento
Director/es
María Cristina Villellas Arilla
A ROLE OF EFFLUX PUMPS IN INTRINSIC DRUG
RESISTANCE AND VIRULENCE OF
MYCOBACTERIUM TUBERCULOSIS
Director/es
        UNIVERSIDAD DE ZARAGOZA        
Bioquímica y Biología Molecular y Celular
Aínsa Claver, José Antonio
Tesis Doctoral
Autor
2013
Repositorio de la Universidad de Zaragoza – Zaguan   http://zaguan.unizar.es
Departamento
Director/es
Director/es
Tesis Doctoral
Autor
Repositorio de la Universidad de Zaragoza – Zaguan   http://zaguan.unizar.es
UNIVERSIDAD DE ZARAGOZA
FACULTAD DE MEDICINA 
DEPARTAMENTO DE MICROBIOLOGÍA, MEDICINA PREVENTIVA Y SALUD 
PÚBLICA 
A role of efflux pumps in intrinsic drug 
resistance and virulence of 
Mycobacterium tuberculosis.  
Memoria presentada por 
 María Cristina Villellas Arilla 
Licenciada en Bioquímica 
Para optar al grado de Doctor por la 
Universidad de Zaragoza 
Director: José A. Aínsa Claver 
 
Dr. José A. Aínsa 
Grupo de Genética de Micobacterias      http://genmico.unizar.es/  
CIBERes – CIBER Enfermedades Respiratorias     http://www.ciberes.org/ 
Departamento de Microbiología, Medicina Preventiva y Salud Pública   Tel : +34-976-761694 
Facultad de Medicina, Universidad de Zaragoza     Fax: +34-976-762420 
C/Domingo Miral s/n, 50009-Zaragoza, Spain     ainsa@unizar.es 
 
 
 
 
 
 
JOSÉ ANTONIO AÍNSA CLAVER, Profesor Titular de Microbiología del 
Departamento de Microbiología, Medicina Preventiva y Salud Pública de la Facultad 
de Medicina, como director de la Tesis Doctoral de MARÍA CRISTINA VILLELLAS 
ARILLA, titulada: 
 
A role of efflux pumps in intrinsic drug resistance and virulence of Mycobacterium 
tuberculosis. 
(Implicación de las bombas de eflujo en la resistencia intrínseca a fármacos y 
virulencia de Mycobacterium tuberculosis) 
 
EXPONE: 
Que esta Tesis Doctoral corresponde con el proyecto de tesis presentado y 
aprobado en su momento, no habiéndose producido ninguna variación. 
Que dicha Tesis doctoral reúne los requisitos necesarios para optar al título de 
Doctor y a la mención de Doctorado Europeo. 
 
Por lo anterior, emito el presente INFORME FAVORABLE. 
 
      Zaragoza, 10 de Diciembre de 2012. 
 
 
 
 
 
Fdo: José A. Aínsa 
 
 
 1 
INDEX OF CONTENTS 
Tabla de contenido 
RESUMEN	  ............................................................................................................................................	  7	  
SUMMARY	  ...........................................................................................................................................	  9	  
Introduction	  
History	  of	  Tuberculosis	  ..............................................................................................................	  13	  
Mycobacteria	  and	  the	  tubercle	  bacillus	  ................................................................................	  14	  
Mycobacterial	  cell	  envelope	  ...............................................................................................................	  16	  
Mycobacterium	  tuberculosis	  complex	  and	  phylogeny	  of	  M.	  tuberculosis	  ...........................	  18	  
Infection	  by	  M.	  tuberculosis	  .................................................................................................................	  19	  
Genomics	  of	  M.	  tuberculosis	  ......................................................................................................	  21	  
Fighting	  against	  tuberculosis	  ...................................................................................................	  22	  
Vaccination	  ...............................................................................................................................................	  22	  
Treatment	  .................................................................................................................................................	  23	  
Drug	  resistance	  and	  tolerance	  of	  M.	  tuberculosis	  ..............................................................	  24	  
Intrinsic	  resistance	  ................................................................................................................................	  24	  
Acquired	  resistance	  ...............................................................................................................................	  25	  
Tolerance	  ...................................................................................................................................................	  26	  
Antibiotics	  against	  tuberculosis	  ........................................................................................................	  26	  The	  Global	  Problem	  of	  TB	  Drug	  Resistance	  and	  the	  Need	  of	  New	  Antibiotics	  .............................	  32	  
Transport	  across	  the	  cell	  envelope	  of	  Bacteria	  ..................................................................	  33	  
Passive	  transport:	  Porins	  .....................................................................................................................	  34	  
Active	  transport:	  Transporters	  ..........................................................................................................	  34	  Families	  of	  Transporters	  .....................................................................................................................................	  35	  
References	  ......................................................................................................................................	  38	  
	  
 
 
 
 2 
CHAPTER	  1	  Role	  of	  MFS	  proteins	  in	  Drug	  Resistance	  and	  Virulence	  of	  M.	  
tuberculosis	  	  
Introduction	  ...................................................................................................................................	  45	  
Efflux	  pumps	  in	  mycobacteria	  have	  important	  roles	  .................................................................	  45	  Drug-­‐resistance	  ........................................................................................................................................................	  45	  Virulence	  .....................................................................................................................................................................	  45	  
Efflux	  pumps	  object	  of	  study	  ...............................................................................................................	  45	  Rv1258c	  (Tap)	  ..........................................................................................................................................................	  45	  Rv1410c	  (P55)	  ..........................................................................................................................................................	  46	  Rv2333c	  (Stp)	  ...........................................................................................................................................................	  47	  
Genetic	  tools	  for	  generating	  knock-­‐out	  strains	  in	  M.	  tuberculosis	  .........................................	  48	  
OBJECTIVES	  ....................................................................................................................................	  49	  
Material	  and	  Methods	  .................................................................................................................	  50	  
Bacterial	  strains,	  media	  and	  growth	  conditions	  ..........................................................................	  50	  
General	  techniques	  of	  nucleic	  acids	  .................................................................................................	  51	  DNA	  extraction	  .........................................................................................................................................................	  51	  Construction	  of	  plasmids	  .....................................................................................................................................	  53	  Oligonucleotides	  ......................................................................................................................................................	  57	  Southern	  Blot	  ............................................................................................................................................................	  58	  
Generation	  of	  competent	  cells	  &	  electroporation	  .......................................................................	  58	  
E.	  coli	  .............................................................................................................................................................................	  58	  
M.	  tuberculosis	  ..........................................................................................................................................................	  59	  
Construction	  of	  knock-­‐out	  strains	  of	  M.	  tuberculosis	  .................................................................	  59	  
Phenotypical	  characterization	  of	  M.	  tuberculosis	  ........................................................................	  61	  Growth	  in	  liquid	  medium	  .....................................................................................................................................	  61	  Neutral	  Red	  Stain	  ....................................................................................................................................................	  61	  
Analysis	  of	  lipids	  of	  M.	  tuberculosis	  cell	  wall	  .................................................................................	  62	  Extraction	  of	  free	  lipids	  and	  mycolic	  acids	  from	  M.	  tuberculosis	  cell	  wall	  ......................................	  62	  Thin	  Layer	  Chromatography	  ..............................................................................................................................	  62	  
Susceptibility	  assays:	  Minimum	  Inhibitory	  Concentration	  ......................................................	  63	  The	  resazurin	  assay	  ................................................................................................................................................	  63	  
Infection	  assays	  .......................................................................................................................................	  64	  
 3 
Intracellular	  replication	  	  in	  J774	  mouse	  macrophages	  ..........................................................................	  64	  Apoptosis	  induction	  in	  J774	  mouse	  macrophages	  ...................................................................................	  64	  Replication	  in	  lungs	  in	  mouse	  model	  .............................................................................................................	  65	  
Results	  and	  Discussion	  ...............................................................................................................	  66	  
Generation	  of	  M.	  tuberculosis	  knock	  out	  mutants	  .......................................................................	  66	  Confirmation	  of	  knock-­‐out	  mutants	  by	  Southern	  Blot	  ...........................................................................	  67	  
Generation	  of	  complementation	  and	  overexpression	  strains	  .................................................	  69	  
Phenotypical	  characterization	  of	  M.	  tuberculosis	  efflux	  pumps	  mutants	  ............................	  71	  The	  generated	  strains	  were	  Neutral	  Red	  positive	  ....................................................................................	  71	  All	  the	  strains	  had	  the	  same	  lipid	  profile	  .....................................................................................................	  71	  H37Rv	  and	  the	  knock	  out	  mutants	  have	  similar	  growth	  rates	  in	  liquid	  medium	  ......................	  72	  The	  P55	  knock-­‐out	  mutant	  and	  overexpressing	  strains	  have	  limited	  growth	  ability	  on	  solid	  media	  ............................................................................................................................................................................	  73	  
Susceptibility	  assays	  ..............................................................................................................................	  74	  
Infection	  assays	  .......................................................................................................................................	  75	  Intracellular	  replication	  in	  J774	  .......................................................................................................................	  75	  Apoptosis	  induction	  in	  cells	  J774	  ....................................................................................................................	  77	  P55	  shows	  an	  attenuated	  phenotype	  in	  mouse	  model	  infection	  .......................................................	  77	  
Conclusions	  ....................................................................................................................................	  79	  
References	  ......................................................................................................................................	  80	  
CHAPTER	  2	  Analysis	  of	  mutations	  conferring	  streptomycin	  resistance	  of	  M.	  
tuberculosis	  reveals	  a	  SNP	  in	  Rv1258c	  gene	  
	  
Manuscript.	  .....................................................................................................................................	  85	  
Comments	  .....................................................................................................................................	  112	  
The	  Beijing	  family	  .................................................................................................................................	  112	  
References	  ...............................................................................................................................................	  113	  
	  
	  
	  
 4 
CHAPTER	  3	  Complementation	  of	  E.	  coli	  efflux	  pumps	  knock	  out	  mutants	  with	  MFS	  and	  RND	  transporters	  of	  M.	  tuberculosis	  
	  
Introduction	  .................................................................................................................................	  117	  
Efflux	  pumps	  from	  RND	  family	  .........................................................................................................	  117	  AcrAB-­‐TolC,	  the	  main	  RND	  efflux	  pump	  in	  E.	  coli	  ..................................................................................	  117	  MmpL	  efflux	  pumps,	  the	  RND	  proteins	  of	  M.	  tuberculosis.	  .................................................................	  117	  
Expression	  of	  heterologous	  genes	  in	  E.	  coli	  .................................................................................	  118	  Influence	  of	  the	  codon	  usage	  ...........................................................................................................................	  118	  
Objectives	  ......................................................................................................................................	  119	  
Materials	  and	  Methods	  .............................................................................................................	  120	  
Bacterial	  strains,	  media	  and	  growth	  conditions	  ........................................................................	  120	  
General	  techniques	  of	  nucleic	  acids	  ...............................................................................................	  121	  Oligonucleotides	  ...................................................................................................................................................	  121	  Plasmid	  DNA	  extraction	  (minipreparation)	  .............................................................................................	  122	  Construction	  of	  plasmids	  ..................................................................................................................................	  122	  
Generation	  of	  E.	  coli	  competent	  cells	  &	  electroporation	  .........................................................	  126	  Electroporation	  .....................................................................................................................................................	  126	  
Construction	  of	  mutants	  by	  Allelic	  Exchange	  in	  E.	  coli	  .............................................................	  126	  
Susceptibility	  assays	  ............................................................................................................................	  128	  
E.	  coli	  ..........................................................................................................................................................................	  128	  
M.	  tuberculosis	  .......................................................................................................................................................	  128	  
Accumulation	  assays	  ...........................................................................................................................	  128	  
Real-­‐time	  accumulation	  and	  efflux	  assays	  ...................................................................................	  129	  Real	  time	  efflux	  assay	  .........................................................................................................................................	  130	  Real-­‐time	  accumulation	  and	  efflux	  assay	  ..................................................................................................	  130	  
Phenotypical	  characterisation	  of	  M.	  tuberculosis	  ......................................................................	  131	  Growth	  in	  liquid	  medium	  ..................................................................................................................................	  131	  Ziehl-­‐Neelsen	  Stain	  ..............................................................................................................................................	  131	  
Results	  ............................................................................................................................................	  133	  
Expression	  of	  efflux	  pumps	  from	  M.	  tuberculosis	  in	  E.	  coli	  .....................................................	  133	  
 5 
Generation	  of	  E.	  coli	  strains	  containing	  M.	  tuberculosis	  efflux	  pumps	  genes	  in	  expression	  vectors	  for	  E.	  coli.	  .................................................................................................................................................	  133	  Generation	  of	  E.	  coli	  strains	  containing	  complete	  or	  partial	  M.	  tuberculosis	  efflux	  pumps	  genes	  in	  its	  chromosome.	  .................................................................................................................................	  133	  Susceptibility	  assays	  of	  E.	  coli	  strains	  with	  M.	  tuberculosis	  efflux	  pumps	  genes	  ......................	  134	  Accumulation	  assays	  ..........................................................................................................................................	  135	  Real	  time	  efflux	  and	  accumulation	  ...............................................................................................................	  136	  
Characterization	  of	  mutants	  MmpL7KO	  and	  MmpL10KO	  of	  M.	  tuberculosis	  ...................	  137	  MmpL7KO	  has	  less	  growth	  rate	  and	  forms	  less	  aggregates	  in	  liquid	  medium	  .........................	  137	  Zielh-­‐Neelsen	  Staining	  .......................................................................................................................................	  139	  Antibiotic	  susceptibility	  of	  MmpL7KO	  and	  MmpL10KO	  ....................................................................	  139	  
CONCLUSIONS	  ..............................................................................................................................	  141	  
References	  ....................................................................................................................................	  142	  
GENERAL	  CONCLUSIONS	  
Conclusiones	  generales	  ............................................................................................................	  151	  
General	  Conclusions	  ..................................................................................................................	  153	  
 
 

 7 
RESUMEN  
 
Las bombas de eflujo son proteínas de membrana que transportan distintos compuestos al 
exterior de la bacteria. Se ha descrito que están implicadas en resistencias intrínseca y 
adquirida a varias drogas, así como en colonización y persistencia de bacterias patógenas 
en el hospedador. Además, diversos procesos fisiológicos pueden verse afectados por estas 
proteínas de membrana, con dependencia de cuál sea el sustrato natural de la bomba de 
eflujo. 
 
En la actualidad, las cepas de Mycobacterium tuberculosis resistentes a antibióticos 
suponen un grave problema de salud. No solo se han descrito cepas multi y extensivamente 
resistentes, si no también resistentes a todos los antibióticos testados. Por ello es 
necesario un esfuerzo a nivel global que permita controlar esta situación  de emergencia. 
Algunas de las estrategias seguidas son: el desarrollo de nuevos antibióticos contra la 
tuberculosis y el programa DOTS (Directly Observed Treatment Short) de la OMS. Un mejor 
conocimiento de los mecanismos de resistencia a antibióticos nos proporcionaría buenas 
herramientas para mejorar el tratamiento antituberculosis. 
 
Las bombas de eflujo MFS Rv1258c (Tap), Rv2333 (Stp) and Rv1410c (P55) de M. 
tuberculosis se habían estudiado previamente en el organismo heterólogo M. bovis BCG, la 
cepa vacunal. Se observó como resultado que éstas estaban implicadas en la resistencia 
intrínseca a varios compuestos. Aunque el modelo de M. bovis BCG es una buena 
aproximación, debido al alto porcentaje de identidad entre M. tuberculosis y M. bovis 
BCG, las pequeñas diferencias en el fondo genético pueden afectar al resultado. Por ello, 
nuestro objetivo principal fue estudiar estas tres bombas de eflujo (Tap, Stp y P55) en el 
microorganismo del que provienen, M. tuberculosis. Se construyeron, derivadas la cepa de 
referencia M. tuberculosis H37Rv, mutantes knock-out para cada una de las bombas, así 
como sus respectivas complementadas, además de las cepas que sobreexpresan el gen de 
la bomba de eflujo. Los ensayos de sensibilidad a antibióticos realizados con estas cepas 
confirmaron la mayoría, aunque no todos, de los resultados en M. bovis BCG. Además, se 
llevaron a cabo experimentos de infección en modelo celular y de ratón, para comprobar si 
la deleción del gen de la correspondiente bomba de eflujo afectaba a la virulencia de M. 
tuberculosis. Atendiendo al modelo celular, las tres bombas de eflujo parecían ser 
necesarias para la virulencia completa de H37Rv; sin embargo, en modelo de ratón 
inmunocompetente, solamente el mutante knock-out de P55 resultó ser atenuado.  
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En búsqueda de otra estrategia para detectar posibles sustratos de bombas de eflujo de M. 
tuberculosis, decidimos intentar expresarlas en Escherichia coli. Además de los ensayos de 
Concentración Inhibitoria Mínima, se realizaron varios ensayos que permiten visualizar la 
acumulación y el eflujo de compuestos el tiempo real. En caso de éxito, esta técnica 
permitiría comprobar rápida y fácilmente una batería de sustratos potenciales de la bomba 
de eflujo. Desafortunadamente, no se obtuvieron resultados significativos; es necesario 
continuar con varios experimentos para confirmar la expresión de las bombas de eflujo 
micobacterianas en E. coli.  En paralelo, caracterizamos el fenotipo de dos mutantes 
knock-out para las bombas de eflujo MmpL7 y MmpL10. La cepa con el gen mmpL7 
delecionado resultó tener una aparentemente mayor velocidad de crecimiento, además de 
que formaba menos agregados al cultivarse en medio líquido que su respectiva cepa wild-
type. 
 
Finalmente, se realizó un análisis de cepas clínicas resistentes a estreptomicina. Se 
secuenciaron los tres genes relacionados con resistencia a estreptomicina (rpsL, rrs y gidB) 
en búsqueda de posibles mutaciones. Un cuarto gen se incluyó en el experimento: 
Rv1258c, que codifica la bomba de eflujo Tap, y que previamente se había descrito que r 
está implicado en la resistencia a estreptomicina. Nuestra hipótesis era que una posible 
mutación en el promotor o en el gen podía conferir resistencia a este antibiótico. Aunque 
no encontramos ninguna mutación que cumpliera este criterio, sí que descubrimos una 
mutación que estaba presente en varias cepas. El análisis en detalle reveló que este SNP 
(Single Nucleotide Polymorphism), denominado Tap580, era específico de las cepas de la 
familia Beijing. Se diseño un método PCR-RFLP que permite detectar fácil y rápidamente 
esta mutación, y posteriormente se validó con un lote de 220 DNA de aislados clínicos 
pertenecientes a diferentes familias de M. tuberculosis.  
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SUMMARY 
Efflux pumps are membrane proteins that transport different substrates to the outside of 
bacteria. It has been reported that they can have a role both in intrinsic and acquired 
resistance to several drugs, and can be implicated in colonization and persistence of 
pathogenic bacteria in the host. In adittion, other physiological processes are also affected 
by these membrane proteins, depending on their natural substrates. 
 
Nowadays, the drug-resistant Mycobacterium tuberculosis strains have become a huge 
health problem. Not only Multi- and eXtensively-Drug Resistant strains, but also M. 
tuberculosis virtually resistant to all antituberculous drugs have been reported. Therefore, 
a global effort has to be made in order to control this emergency situation. Several 
strategies are in progress: the development of new anti-TB drugs and Directly Observed 
Treatment Short courses (DOTS) are among them. A better understanding of the 
mechanisms of drug-resistance would provide useful tools to improve therapy. 
 
The MFS efflux pumps Rv1258c (Tap), Rv2333 (Stp) and Rv1410c (P55) from M. tuberculosis 
have been previously studied in the heterologous host M. bovis BCG, the vaccine strain. A 
clear role in intrinsic resistance was observed for several drugs. Although this a good 
approximation, since the high percentaje of identity between M. tuberculosis and M. bovis 
BCG, the little differences in the genetic background could affect the results. For this, our 
main objective was to study these three efflux pumps in their own microorganism, M. 
tuberculosis. Knock-out and complemented strains, along with overexpression strains were 
generated for Tap, Stp and P55, derived from the virulent M. tuberculosis reference strain 
H37Rv. Susceptibility assays confirmed most, but not all, of the results obtained in M. 
bovis BCG. Infection assays were performed in cell and mouse model, to test if the 
deletion of the efflux pump gene affected pathogenicity. According to cell model, the 
three efflux pumps seemed to be necessary for complete virulence of M. tuberculosis; 
nontheless, in immunocompetent mouse model, only P55-knock out proved to be 
attenuated. 
 
In search for another strategy to detect substrates of efflux pumps from M. tuberculosis, 
we decided to try to express them in Escherichia coli. In addition to Minimun Inhibitory 
Concentration assays, a experiment in which the accumulation and efflux of molecules can 
be observed in real time was optimised. If successful, the technique would allow to easily 
and quickly test a range of potential substrates of the target efflux pump. Unfortunately, 
no significant results were obtained and further experiments would be required to confirm 
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the expression of the mycobacterial efflux pumps in E. coli. In parallel, two M. 
tuberculosis knock out mutants for the efflux pumps MmpL7 and MmpL10 were 
phenotypically characterised. Interestingly, the strain which had mmpL7 disrupted showed 
an apparent increase in the growth rate, as well as less aggregates than the wild type 
strain when it was grown in liquid medium.  
 
Finally, an analysis of streptomycin-resistant clinical isolates was done. The genes already 
related to streptomycin resistance (rpsL, rrs and gidB) were sequenced and analysed in 
search of mutations. A fourth gene was included in this experiment: Rv1258c, encoding 
Tap efflux pump. Since this transporter is implicated in streptomycin resistance, our 
hypothesis was that a possible mutation in the promoter or in the gene could be conferring 
resistance. Although we didn’t find any mutations in tap gene fulfilling this criteria, we did 
notice a mutation that several clinical isolates had in common. Further research revealed 
that this Single Nucleotide Polymorphism (SNP), called Tap580, was specific of Beijing 
lineage of strains. A quick PCR-RFLP method to easily detect this mutation was designed, 
and checked with a lot of 220 DNA extractions of clinical isolates belonging to different 
lineages of M. tuberculosis.  
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History of Tuberculosis 
The disease is caused by Mycobacterium tuberculosis, a bacillus whose history is closely 
related to that of mankind, as it has infected humans for thousands of years. Pathological 
evidence of TB has been found in Egyptian mummies dating back five millennia, and a 
specific DNA sequence unique to M. tuberculosis has been identified in Egyptian and 
Peruvian mummies dating back to 500-1500 Before Christ (BC). By the first millennium BC, 
tuberculosis was endemic all around the world, and named phtisis, the Greek term for 
consumption. At that time (460 BC), phtisis was the most widespread disease in Ancient 
Greece. 
 
It was not until XVII and XVIII centuries After Christ (AC) that there was an advance in the 
understanding of the disease. The 17th century German physician Franciscus Sylvius firstly 
described the “tubercles” as characteristic lesions in the lung of people suffering from 
phtisis, and almost 200 years later, this discovery will further name the disease as 
“tuberculosis”. Some studies performed between 1600 and 1800 AC, had suggested that 
the main infective agent was the sputum of ill patients, and it was even proposed that 
tuberculosis was caused by some animacula, or wonderfully minute living creatures. This 
hypothesis, published in 1719 by Benjamin Marten, was considered ridiculous. 
 
From second half of the XVIII century until the end of the XIX, TB was a prevalent disease 
in Europe and North America, and was called white plague for the extreme paleness of 
people suffering from this disease. But XIX century is also the century of scientific 
advances and a marked decrease in deaths caused by tuberculosis was about to happen. 
It was in 1882 when Robert Koch first observed M. tuberculosis (that was also named “Koch 
bacillus” in his honor) under the microscope, and published a demonstration that it was 
the etiological agent of tuberculosis. He had previously presented the Koch’s Postulates, 
describing how an infectious microorganism isolated from a lesion of a person or animal 
suffering the disease, can reinfect a healthy animal; those postulates are currently the 
basis of medical microbiology. 
 
Since then, great advances in fight against TB have happened incessantly. In 1921 Albert 
Calmette and Camille Guerin obtained the current vaccine against TB, named BCG (Bacille 
de Calmette et Guerin). In 1944 Schatz and Waksman discovered streptomycin, an 
antibiotic with antimycobacterial activity. This fact, followed by the discovery of isoniazid 
in 1952 and rifampicin in 1967, marks a new period for tuberculosis. It turned into a 
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curable disease and new cases decreased considerably until the ‘80s. Appearance of HIV in 
addition to other factors, such as migrations, caused then the reemergence of tuberculosis 
and other diseases, and in 1993 it was declared an emerging global health problem by the 
WHO (Fig. 1.). 
 
 
 
Nowadays, the emergence of strains that are resistant to the current therapy complicates 
the aim of TB eradication. However, we count currently on great scientific advances, 
including the knowledge of the complete genome of M. tuberculosis (27) that will allow us 
to better understand the biology and molecular mechanisms of the bacillus, to efficiently 
win this fight. 
Mycobacteria and the tubercle bacillus  
Mycobacteria are acid-fast bacilli belonging to the genus Mycobacterium, family 
Mycobacteriaceae, included into the suborder Corynebacteriaceae, order Actinomycetales 
(94). Philogenetically they belong to the gram-positive group of bacteria, however, due to 
their highly hydrophobic cell wall, different from those of both gram positive and gram 
negative bacteria, they are only weakly stained by gram staining.  
Fig. 1. Timeline in TB research. It shows the most relevant highlights in the fight against the disease. 
Adapted from (51). 
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The genus Mycobacterium comprises more than 120 species (98). They include 
nonpathogens, e.g. Mycobacterium smegmatis, as well as highly successful pathogens e.g. 
Mycobacterium tuberculosis, Mycobacterium leprae and Mycobacterium ulcerans, the 
etiologic agents of tuberculosis, leprosy and Buruli ulcer, respectively. Attending to the 
rate of replication, mycobacterial species can be divided in two groups: slow-growing 
mycobacteria, with a doubling time higher than 13 hours, like M. tuberculosis, and rapid-
growing mycobacteria, with a generation time between 2 and 5h, like M. smegmatis. 
 
Colony morphology is variable among species, from rough to smooth and pigmented to non-
pigmented. Mycobacteria inhabit various environmental reservoirs, like ground and tap 
water, soil, animals and humans. They can grow in fluid environments, usually forming 
clumps because of their high hydrophobic cell envelope; some mycobacteria are invasive, 
since they are able to multiply inside macrophages, such us M. tuberculosis.  
 
Classically, the genus Mycobacterium has been organised in a phylogenetic tree attending 
the homology level of 16S RNA gene (Fig. 2.) (38); in adittion, other genes have been 
analysed as well in order to reach a more robust phylogeny (99). 
 
M. tuberculosis is an aerobic bacillus, catalase and nitrate reductase positive, non-motile 
and non-sporulated, of 2-5µm in length and 0.2-0.5µm in width. Its doubling time (~24h) 
classifies it as a slow-grower, which needs 4 weeks to form a colony on solid medium. Until 
recently, it was believed that mycobacterial species don’t sporulate, but a study by Ghosh 
et al.(39) revealed that M. marinum and most likely M. bovis BCG, actually can form 
spores. 
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Mycobacterial cell envelope 
The basic architecture of the mycobacterial cell envelope differs from the ones of gram 
positive and gram negative bacteria. The Mycobacterium tuberculosis envelope, from the 
inside to the outside, consists of a plasma membrane, similar to other plasma membranes 
(28); a cell wall composed of three covalently linked macromolecules (peptidoglycan, 
arabinogalactan and mycolic acids) and noncovalently linked lipids and proteins; and a 
capsule consisting of polysaccharides, proteins and lipids (Fig. 3.) (72). The 
Fig 2. Phylogenetic tree of the genus Mycobacterium based on 16S RNA homology. Rapid and slow 
growers are separated with a dotted line, virulent strains are underlined. Adapted from (38). 
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lipopolysacharides lipomannan (LM) and lipoarabinomannan (LAM) are not covalently 
attached to the mycobacterial envelope, and their localization remains unclear (40). The 
non-covalent associaton of mycolic acids and complex free lipids conforms an atypical 
outer membrane (45). In M. tuberculosis, these free lipids include the phthiocerol 
dimycocerosates (PDIM) and the closely related phenolic glycolipids (PGL), the trehalose 
ester families that include sulfolipids (SL), diacyltrehaloses (DAT) and polyacyltrehaloses 
(PAT), and the family of mannosyl-β-1-phosphomycoketides (46). The trehalose dimycolate 
(TDM) or “cord factor”, named so before discovering its chemical structure, is also a free 
lipid implicated in cording, and constituted the first virulence factor of M. tuberculosis 
(41). 
 
Important functions are related with the mycobacterial envelope, such us defining the 
shape of the cell and providing mechanical and osmotic protection. Other important 
function is the transport of molecules, including nutrients, ions, antibiotics and toxic 
metabolites. Its unually high hidrophobicity makes it an efficient barrier for antibiotics, 
thus contributing to intrinsic drug resistance. Regarding M. tuberculosis, when infecting 
macrophages, the cell wall is the primary interface between the bacterium and the host, 
constituting the first line of defense against host attacks. In adittion, some complex free 
lipids, such us PDIM, are known to be virulence factors, and others contribute to modulate 
the immune response from the host (9). 
 
Such a lipid-rich coat explains the tendency of mycobacteria to form aggregates when 
grown in liquid medium, as well as the property of acid fastness. The characteristic cell 
wall of mycobacteria retains the dye carbol-fuchsin after a wash with an alcoholic solution 
in acid medium (Ziehl-Neelsen stain), whereas the rest of bacteria are quickly decolorized. 
It was recently suggested that this is a consequence of the density of mycolic acids (111). 
 
In addition, the fixation of the dye neutral red is used as a marker of virulence, since this 
dye indicates important alterations in the cell envelope of M. tuberculosis. Specifically, 
neutral red is unable to fix to the cell envelope when bacteria are deficient in more than 
one type of methyl-branched lipids, which are related to virulence, such us PDIM (26). 
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Mycobacterium tuberculosis complex and phylogeny of M. tuberculosis 
The Mycobacterium tuberculosis complex (MTBC) is composed by all the etiologic agents of 
tuberculosis, and currently includes nine species.  
 
Species Host 
M. tuberculosis Human 
M. africanum Human 
M. canettii Human 
M. bovis Cattle 
M. caprae Goat 
M. microti Vole 
M. pinipedii Seal and sea lion 
M. mungi Mongoose 
M. orygis Oryx 
 
 
 
Table 1. Species belonging to MTBC  (5, 103) 
Fig. 3. Schematic representation of cell envelope of M. tuberculosis. Adapted from (72) 
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The development of techniques such us IS6110 RFLP (102), spoligotyping (42, 49), 
Mycobacterial Interspersed Repetitive Units (MIRU) (96) and more recently, Single 
Nucleotide Polymorphism (SNP) (36, 44) and Large Sequence Polymorphism (LSP) 
genotyping (66, 100), have led to the intraespecific classification of M. tuberculosis strains 
into several lineages: East African-Indian (EAI) lineage, Beijing lineage, Central-Asian (CAS) 
or Delhi lineage, Haarlem family, Latin American and Mediterranean (LAM) family, X 
family, T families and others. (83) 
 
Infection by M. tuberculosis  
Tuberculosis is a contagious disease (114). Infection with M. tuberculosis occurs through 
inhalation of aerosols containing the bacteria which are spread by persons with active 
pulmonary TB. After inhalation, bacteria are settled in the alveoli and disseminated by the 
lymphatic circulation. Further dissemination to other parts of the lung and occasionally to 
other organs is achieved by haematogenous circulation. The most common form of the 
disease is pulmonary tuberculosis, although TB-meningitis, miliary (disseminated) 
tuberculosis, lymphadenitis, osteomyelitis and Pott’s disease (affected bones) also occur 
(114). Primary infection leads to active disease in about 10% of infected individuals, in 80% 
Fig 4. Updated phylogeny of the MTBC. Adapted from (103). 
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of the cases in the period of two years (126). In the remaining 90%, the immune system 
controls the infection, and the individual is non- infectious and asymptomatic. In this 
clinical state the TB bacilli can lie dormant for years (latent TB) (103). However, when the 
immune system is weakened, the latent infection can reactivate (114, 126). In an HIV-
infected person the risk of reactivation of latent TB is higher than 10% per year, compared 
to a lifetime risk of 10-20% for HIV- negative individuals (24, 112, 126). 
 
Once the bacteria are phagocytosed by alveolar macrophages, mediated by specific 
macrophage receptors (37, 39, 63, 111), a localized proinflammatory response that leads 
to recruitment of mononuclear cells from neighboring blood vessels is induced. These cells 
will build the granuloma (necessary to contain infection) which consists of a group of 
infected macrophages, surrounded by foamy giant cells (multinuclear macrophages loaded 
with lipids) and macrophages with a layer of lymphocytes delineating its periphery (102-
104) (Figure 2). 
 
Activated macrophages promote phagosomal maturation by a process that finally involves 
fusion with lysosomes and formation of the phagolysosome. These vesicles provide a 
hostile environment for the bacilli including acid pH, reactive oxygen intermediates (ROI), 
lysosomal enzymes and toxic peptides. M. tuberculosis has evolved to survive within 
macrophages by arresting the normal phagosomal maturation at an early stage, thereby 
restricting its acidification and limiting fusion with lysosomes (91, 99). Modulation of 
phagosome maturation seems to be mainly mediated by both mycobacterial cell-wall lipids 
and other bacterial effectors (e.g., SapM or PknG) (47, 133, 134). Additionally, the 
screening of shotgun libraries has enabled the isolation of several M. tuberculosis mutants 
unable to induce phagosomal arrest (97, 119). Apart from surviving within the macrophage, 
pathogenic mycobacteria have also been suggested to escape into the cytosol in an ESX-1-
dependent manner (129). In addition, M. tuberculosis reduces phagosome acidification by 
the exclusion of the proton- ATPase (120) and decreases ROI and nitric oxide (NO) synthesis 
and cytokine production by modulating Ca2+ fluxes in infected macrophages (77). Moreover, 
M. tuberculosis has evolved multiple strategies to detoxify ROI and RNI (38). Recently, 
authophagy (30, 58) and apoptosis (69) have been postulated as effective 
antimycobacterial mechanisms. 
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Genomics of M. tuberculosis 
The complete genome sequence of the most studied and the best understood strain of M. 
tuberculosis, H37Rv, was obtained in 1998 (114) and revised and re-annotated in 2002 and 
it is in continuous revision (as of August 2010; NCBI Entrez Genome Project). Complete 
genome sequences are now available for five M. tuberculosis strains, CDC1551, F11, 
H37Ra, H37Rv and KZN1435, and sequencing of 71 other M. tuberculosis genomes is in 
progress providing a valuable tool for research using genetic techniques (71). This 
information is available in sequencing websites, as well as in several online databases 
(http://tuberculist.epfl.ch/, http://www.ncbi.nlm.nih.gov/ or 
http://www.microbesonline.org/). 
 
The genome comprises 4,411,532 bp, with a G+C content of 65.9% (22). Only a few regions 
show a skew in this G+C content. A conspicuous group of genes with a very high G+C 
content (> 80%) appear to be unique in mycobacteria and belong to the family of PE or PPE 
proteins. In turn, the few genes with particularly low (< 50%) G+C content are those coding 
for transmembrane proteins or polyketide synthases. This deviation to low G+C content is 
believed to be a consequence of the required hydrophobic amino acids, essential in any 
transmembrane domain, that are coded by low G+C content codons. The last re-annotation 
identified 4090 genes thought to encode 3,989 proteins and 71 stable RNAs (Figure 4) (71). 
Some outstanding features include the great abundance of genes involved in lipid 
metabolism which is indicative of the highly active metabolism mainly in relation with the 
cell envelope. There are genes encoding for 250 distinct enzymes involved in fatty acid 
metabolism, compared to only 50 in the genome of Escherichia coli (21). The PE- PPE 
family of proteins, which represents approximately 4% of the genome, includes 168 genes. 
The names come from Pro-Glu (PE) and Pro-Pro-Glu (PPE) sequences found in the two 
conserved N-terminal regions in each of these protein families that are approximately 110 
Fig. 5: Progression of TB granuloma. In 
the early stage, the granuloma has a 
core of infected macrophages enclosed 
by foamy macrophages and other 
mononuclear phagocytes, surrounded by 
lymphocytes. As the granuloma matures, 
it develops a fibrous capsule that 
encases the macrophage core and 
excludes the majority of lymphocytes 
from the center of the structure. Adapted 
from (85). 
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and 180 amino acids long, respectively. Although the function of the members of the PE 
and PPE protein families has not been established, they are suggested to be involved in 
antigenic variation and disease pathogenesis (29). Tubercle bacilli also contain complex 
regulatory machinery comprising 11 two component systems, 11 serine/threonine protein 
kinases, 13 σ factors, and over 100 repressors and activators, suggesting a tight regulation 
of transcription in response to different stimuli. Interestingly, the analysis of the DNA 
metabolic system of M. tuberculosis indicates a very efficient DNA repair system, in other 
words, replication machinery of exceptionally high fidelity. The genome of M. tuberculosis 
lacks the MutS- based mismatch repair system. However, this absence is overcome by the 
presence of nearly 45 genes related to DNA repair mechanisms (88), including three copies 
of the mutT gene. This gene encodes the enzyme in charge of removing oxidized guanines 
whose incorporation during replication causes base-pair mismatching (21, 88). Repetitive 
DNA is very important in mycobacterial genomes. Elements like Tandem Repeats, 
Interspersed Repeats, and mobile genetic elements are common. In H37Rv, 56 loci with 
similarity to IS elements have been found that can be classified into major IS families (IS3, 
IS5, IS605 or IS21). Mobile genetic elements will be widely analyzed in the following 
section as they could have an important role in genome plasticity and the virulence of the 
bacilli. 
Fighting against tuberculosis 
At the middle of the twentieth century the eradication of tuberculosis was considered 
feasible. Although several problems were anticipated, it was thought possible to 
strengthen the control programs of the disease to the point of its total elimination. The 
failure of these predictions became obvious when in 1986 the downward trend of the 
incidence rate of tuberculosis reversed. The reasons are several and complex, including 
the arrival and spread of HIV infection, the immigration of people from high-prevalence 
countries and the deterioration of tuberculosis control. Nowadays, the goal to eliminate 
tuberculosis has been set for 2050, but it will not be met with present strategies and 
instruments, thus a strong effort is being made to improve both prevention and treatment 
of this deasease. 
Vaccination 
BCG is one of the most widely used vaccine today (> 80 % of neonates and infants in some 
countries). Although it does not prevent primary infection or reactivation of latent 
pulmonary TB, the principal source of bacillary spread in the community, BCG protects 
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against disseminated forms of TB, especially against meningitis in children. For that 
reason, BCG vaccination is still recommended by the WHO and applied widely (116, 124). 
 
After its first use in humans in 1921, propagation of BCG in non-standardized conditions in 
different laboratories all around the world gave rise to different variant strains that differ 
in genotype and phenotypic characteristics (9). Strain differences could be one cause of 
the variable protective efficacy afforded by BCG (45), but other factors such as population 
genetics or exposure to environmental mycobacteria could be implicated (29). 
 
Due to this inconsistency in protective efficacy, and to the inability of BCG to prevent 
pulmonary forms of tuberculosis and consequently, to prevent transmission of the disease, 
great efforts are being made by governments, research institutions and private foundations 
for constructing and testing new promising vaccine candidates. 
 
Treatment  
The aims of treatment of tuberculosis are: 
• to cure the patient and restore quality of life and productivity. 
• to prevent death from active TB or its late effects. 
• to prevent relapse of TB. 
• to reduce transmission of TB to others. 
• to prevent the development and transmission of drug resistance. 
 
The antibiotics active against tuberculosis can be divided in first-line and second-line 
drugs. First line agents are generally those with the greatest bactericidal activity and they 
form the core of TB treatment. Second-line agents are normally bacteriostatic, they have 
more adverse effects, and are commonly used in case of disease caused by strains resistant 
to first-line drugs. (Table 2.) 
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Tuberculosis treatment requires long courses (around 6 to 12 months) of multiple 
antibiotics. It consist of an initial intensive phase of treatment (2 months) with RIF, INH, 
PAZ and either EMB or SM designed to kill actively growing and semi-dormant bacilli, 
followed by a continuation phase (4 months) with RIF and INH to eliminate residual bacilli 
and reduce the number of relapses. To complete the treatment it is critical to reduce the 
development of acquired drug resistance and therefore trained individual personnel 
supervises that the patient takes each dose of medication. This strategy is known as 
directly observed treatment short-course (DOTS) and was promoted as the official policy of 
the WHO in 1991 (137). 
 
Drug resistance and tolerance of M. tuberculosis 
Intrinsic resistance 
The thick and highly hydrophobic mycobacterial cell wall envelope is an effective 
permeability barrier to many antibiotics, being one of the main causes of the high, 
intrinsic antibiotic resistance in mycobacteria (20). But there are other mechanisms or 
genes likely contributing to it. 
 
M. tuberculosis is known to contain numerous genes encoding efflux pumps belonging to 
different families (30, 36). It has been reported that overexpression of some genes 
encoding efflux pumps confers resistance to different drugs in different mycobacteria, as 
shown in Table 2, and it is becoming evident the implication of efflux mechanisms in the 
intrinsic resistance to drugs. 
First-line drugs Second-line drugs 
Isoniazid Ethionamide 
Rifampin Cycloserine 
Pyrazinamide Para-amino salicylic acid 
Ethambutol Capreomycin 
Streptomycin Kanamycin 
 Amikacin 
 Quinolones (Moxifloxacin, Levofloxacin, 
Gatifloxacin, Ciprofloxacin) 
 Linezolid 
Table 2. Drugs used in treatment of tuberculosis. (50) 
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In addition to efflux pumps, mycobacteria produce some drug-modifying enzymes, such as 
β-lactamases, responsible for the intrinsic resistance to β-lactams drugs in M. tuberculosis 
(73). 
 
The gene erm37 (or ermMT) encodes a 23S rRNA methyltransferase, which is responsible 
for intrinsic resistance to macrolides (9, 23) not only in M. tuberculosis but also in other 
mycobacteria (97-99). 
 
Aminoglycoside modifying enzymes are also present in the chromosome of M. tuberculosis 
and other mycobacteria but their role in resistance is unclear, as two of those genes, 
aac(2’)-Ic from M. tuberculosis and aac(2’)-Id from M. smegmatis, were studied in M. 
smegmatis and only aac(2’)-Id was correlated with aminoglycoside resistance (6, 90). 
 
It has been reported that whiB7, a transcriptional activator, was responsible for intrinsic 
resistance to several antibiotics of different structures, like erythromycin, 
chloramphenicol, clarithromycin, spectinomycin, streptomycin or tetracycline (94). It has 
been shown that whiB7 is a regulator that may be involved in the induction of some 
previously described genes, including the gene encoding for the efflux pump tap, or the 
gene erm37. There are 7 whiB genes in M. tuberculosis (whiB1-whiB7) induced by different 
stress conditions and antibiotics (52, 134), and some homologous ones which have already 
been found in M. smegmatis (114). 
 
Acquired resistance 
Bacteria can become resistant to antibiotics by several strategies: i) target modification, 
ii) target overexpression, iii) barrier mechanisms (reduce uptake or increased efflux), iv) 
drug-inactivating enzymes, v) inactivation of drug-activating enzymes. Genes conferring 
resistance can be located in plasmids or transposons, and therefore can be transferred 
horizontally from one strain to another (50) . 
 
M. tuberculosis is able to acquire resistance by mutation in its chromosomal genes; this 
will be further detailed in the mechanism of resistance of each antituberculous antibiotic. 
No horizontal transfer of resistance genes had been reported for M. tuberculosis (50). 
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Tolerance 
Tolerance is defined as the phenotypic resistance or non-susceptibility to a drug mediated 
by changes in a cells’s physiological state, which is often associated with non-replicating 
state as in persisters (50). It has been reported that, upon macrophage infection, bacterial 
efflux pumps confer tolerance (Fig. 6) (1); however, the mechanisms underlying this 
transient resistance are not fully understood. 
 
 
 
Antibiotics against tuberculosis 
In this section, mechanism of action and drug resistance are explained for each anti 
tuberculosis drug. 
First-line antibiotics  
Isoniazid	  
Isoniazid (isonicotinic acid hydrazide, INH) is one of the most-widely used first-line TB 
antibiotics, utilized both in standard chemotherapy as well as in chemoprophylaxis (166). 
It is highly active against growing tubercle bacilli but has little activity against resting 
bacilli in stationary phase or under anaerobic conditions (93). 
 
Isoniazid is a prodrug that becomes active thanks to the action of the catalase peroxidase 
encoded by the gene katG (167). The current mode of action proposes that, when 
activated, INH binds to NAD forming an INH-NAD adduct. This adduct binds and inhibits 
InhA (an enoyl-acyl carrier protein reductase involved in mycolic acid biosynthesis), 
Fig. 6. Antibiotic Tolerance in Replicating 
Mycobacteria Mediated by Macrophage-Induced 
Drug Efflux (A) Extracellular mycobacteria are killed 
and eliminated by antibiotics. (B) Mycobacteria that 
enter macrophages may retain susceptibility to drugs 
and be killed, or they may induce expression of efflux 
pumps, which makes them drug tolerant and able to 
replicate and persist in the face of otherwise lethal 
concentrations of antibiotics. (1, 76) 
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consequently inhibiting mycolic acid biosynthesis and inducing cell death (154) (Fig. 4). 
InhA is accepted to be the target of INH. 
 
Loss of KatG activity implies a failure in activating INH (155), hence mutations in the katG 
gene are cause of resistance. Indeed, between 20 and 86% of INH resistant strains 
(depending on the geographical region) contain a mutation in the katG gene, being the 
mutation S315T the most common. 
 
Fifteen to forty-six percent of the resistant mutants present a mutation on the promoter 
region of the inhA gene. Those mutations have led to an increased expression of this gene, 
and cause low level of INH resistance (170) and co-resistance with ethionamide, as both 
drugs act on the same target InhA (154). 
 
Although most INH resistant strains have mutations in katG and inhA, other genes have 
been postulated to have some implication in INH resistance, like ndh-II, ahpC or kasA. 
Some efflux pumps, including mmpL7 or the pump component iniA have been reported to 
be involved in INH resistance (67). 
 
Rifampicin	  
Rifampicin (RIF) is a semisynthetic first- line antibiotic for the treatment of TB but is also a 
broad spectrum antibiotic active against a wide range of bacteria. 
 
RIF is active against growing M. tuberculosis and stationary phase bacilli with low 
metabolic activity. RIF inhibits RNA synthesis by binding to the bacterial RNA polymerase 
(25). 
Resistance to RIF in M. tuberculosis, as in many other bacteria, is caused by mutations in the 
rpoB gene that encodes the β-subunit of the RNA polymerase. Those mutations are found in 
about 96 % of RIF-resistant TB isolates (146). 
 
In addition, it has been found that the deletion of the Rv1410c gene encoding the P55 
efflux pump made M. bovis BCG more susceptible to a range of toxic compounds including 
rifampicin (117). 
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Ethambutol	  
Ethambutol (EMB) is a mycobacteria-specific drug with no apparent activity against other 
bacteria. It has a bacteriostatic activity only against actively growing bacilli, having no 
effect on non-replicating bacilli (164). 
The proposed target of EMB is the arabinosyl transferase, an enzyme involved in synthesis 
of arabinogalactan - the major polysaccharide of the mycobacterial cell wall (91). EMB 
then inhibits the synthesis of arabinogalactan, interfering with the polymerization of cell 
wall arabinan (144). 
 
The enzyme arabinosyl transferase is encoded by the gene embB, which is part of an 
operon containing the genes embC-embA-embB in M. tuberculosis. Up to 68% of the EMB-
resistant clinical isolates presents mutations in the embCAB operon (147,140). Other genes 
including Rv0340, rmlD or rmlA2, have been found to be associated with EMB resistance 
(115), though they are not significant. 
 
Around 25% of EMB-resistant M. tuberculosis strains do not have mutations in any of the 
genes described, suggesting that there may be other mechanisms involved in EMB 
resistance. 
 
Pyrazinamid	  
Pyrazinamide (PZA) is a first-line antibiotic used in the initial phase of treatment that is 
very active against M. tuberculosis, while other bacteria, including other mycobacteria, 
are not susceptible. PZA is only active at acid pH (86), showing activity in vivo but not in 
vitro. Uncommonly, it kills non-growing bacilli with low metabolic activity more efficiently 
than actively growing bacilli (171). 
 
The proposed mode of action of PZA (Fig. 6) suggests that it enters the bacilli and is 
converted into pyrazinoic acid (POA) by the action of pyrazinamidase/nicotinamidase 
enzyme, encoded by the pncA gene. POA gets out of the cell by passive diffusion and weak 
efflux (in M. tuberculosis it seems to be rather defective), and in an acidic extracellular 
environment, a portion of POA becomes protonated to HPOA, the uncharged form that 
permeates through the membrane inside the cell. HPOA brings protons into the cell, what 
could cause cytoplasmatic acidification and de-energization of the membrane by collapse 
of the proton motive force further affecting membrane transport (168). 
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Thus most PZA-resistant M. tuberculosis strains (72 – 97 %) present mutations in the pncA 
gene, losing the pyrazinamidase/nicotinamidase activity and failing in the activation of the 
prodrug (131, 132). However, while M. tuberculosis is uniquely susceptible to this drug, 
other mycobacteria are intrinsically resistant. In the case of M. bovis, this resistance is due 
to a SNP in the pncA gene with respect to M. tuberculosis, which causes lack in PZase 
activity (130). In M. smegmatis and other mycobacteria, the resistance is suggested to be 
due to an active efflux of POA (169). There are still some resistant TB strains whose 
mechanism of resistance to PZA still has to be determined. 
Streptomycin	  
Streptomycin (SM) is an aminoglycoside antibiotic discovered in 1944 (1) that was the first 
effective TB drug. Aminoglycosides are broad-spectrum antibiotics with a bactericidal 
activity against a variety of bacterial species including M. tuberculosis. SM kills actively 
growing bacilli, while it has no effect on non-growing or intracellular tubercle bacilli (92). 
Due to the severe adverse effects that can cause and also because it is an injectable drug, 
it has been relegated as a second-line TB drug. 
 
SM inhibits protein synthesis by binding to the 30S subunit of the bacterial ribosome, 
specifically to the ribosomal protein S12 and the 16S rRNA (51). It can also cause damage 
to the cell membrane. 
 
SM resistance in M. tuberculosis is due to mutations in the genes rpsL and rrs which encode 
respectively the S12 protein and the 16S rRNA of the ribosome, that is the SM target (47). 
Approximately 70% of the SM-resistant clinical isolates have a mutation in one of those two 
genes, resulting in intermediate or high level of resistance. There are still 20-30% of the 
resistant strains presenting low level resistance with no mutation found (164), which 
suggests that there are other mechanisms of resistance. 
 
For example, Tap efflux pump has been shown to confer low level resistance to SM when 
overexpressed (3). In addition, it has recently been found that mutations within the gene 
gidB (encoding a 7-methylguanosine (m(7)G) methyltransferase specific for the 16S rRNA) 
confer low-level streptomycin resistance by loss of a conserved m(7)G modification in 16S 
rRNA (102). 
 
Despite the existence of aminoglycoside modifying enzymes, their role in clinically 
relevant resistance still remains unclear since none appears to have SM as a substrate. 
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Second-line antibiotics 
 
Fluoroquinolones	  
Fluoroquinolones are drugs with a broad-spectrum bactericidal activity against a wide 
range of bacteria, including mycobacteria. They are known to inhibit DNA gyrase complex, 
as well as DNA topoisomerase IV. Mutations in gyrA and gyrB (genes encoding the two 
subunits of DNA gyrase) cause resistance to quinolones in M. tuberculosis, which does not 
have topoisomerase IV. However, there are some mutants in which DNA gyrase is not 
involved, and the mechanism of their resistance is not clear (41). 
 
A new mechanism of quinolone resistance was recently identified. MfpA is a protein that 
binds to DNA gyrase and inhibits its activity, also giving FQ resistance (59). 
 
Aminoglycosides	  
Other aminoglycosides besides SM, such as kanamycin, gentamicin, amikacin, or 
capreomycin – which is a peptide antibiotic but commonly grouped with the 
aminoglycosides - that are not first-line drugs for TB treatment, play an important role in 
the treatment of MDR strains or infections with mycobacteria other than M. tuberculosis. 
 
Since they are aminoglycosides, and they bind to ribosomal structures at the 16S rRNA, 
mutations in rrs gene are also cause of resistance (7, 66) even though they do not cause 
cross resistance with SM. 
 
Recently, it has been described that tlyA, a gene encoding an rRNA 2’-O- 
methyltransferase, is involved in capreomycin and viomycin resistance (84). 
 
In mycobacteria there are some chromosomally encoded aminoglycoside modifying 
enzymes that only confer resistance to some agents in the case of M. smegmatis (5, 6, 90). 
 
Cycloserine	  
Cycloserine is a bacteriostatic antibiotic used as a second-line agent often in combination 
with other second-line drugs to treat MDR TB. It inhibits the synthesis of peptidoglycan by 
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blocking the action of D-alanine racemase and D-alanine:alanine synthase but the genetic 
bases of CS resistance are unclear (164) 
 
PAS	  
PAS (Para-Amino Salicilic acid) is a bacteriostatic antibiotic active against TB and other 
mycobacteria but not against non-mycobacterial species. It is used as a second-line drug in 
combination with others to treat MDR-TB. 
 
The mechanism of action of PAS is not well understood, though two possible mechanisms 
have been proposed: interference with folic acid biosynthesis (120) and inhibition of iron 
uptake (118). 
 
The gene thyA, encoding a thymidilate synthase has been reported recently to be involved 
in PAS resistance in some clinical isolates (120). 
 
Ethionamide	  
Ethionamide (ETH) is a derivative of isonicotinic acid, and is a second-line anti TB drug. It 
shares a common target with INH, the enoyl-acyl carrier protein reductase (InhA) involved 
in mycolic acid biosynthesis. Therefore it inhibits mycolic acid biosynthesis and causes cell 
death. 
ETH is a prodrug that needs to be activated. This activation is done by oxidation, thanks to 
an enzyme codified by the gene etaA, also called ethA. Consequently, mutations in ethA 
cause resistance to ETH (164). 
 
Mutations on the promoter region of the inhA gene leading to increased expression, cause 
low level of ETH resistance and co-resistance with INH, as both drugs act on the same 
target InhA (154). 
 
The mechanism of action and target are the same for ETH and INH, so the resistance 
mechanisms described for INH are valid for ETH and if common, they cause co- resistance. 
The different step is the activation of the prodrug, carried out by KatG in case of INH, and 
EthA in case of ETH. 
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The Global Problem of TB Drug Resistance and the Need of New Antibiotics 
MDR-, XDR- and TDR-TB strains 
Multi Drug-Resistant Tuberculosis (MDR-TB), is the disease caused by bacilli resistant to at 
least isoniazid and rifampicin, the two most powerful anti-TB drugs.  
 
It can take up to two years to treat with drugs that are more toxic, more expensive, and 
less effective than the first-line ones. If the drugs to treat MDR-TB are mismanaged, 
further resistance can occur. In 2006 a new type of resistant TB was described - XDR-TB 
(eXtensively Drug-Resistant TB) – which is more dangerous, and threatens all the TB control 
efforts (156). XDR is defined as: “resistant to at least rifampicin and isoniazid, in addition 
to any fluoroquinolone, and at least one of the three following injectable drugs used in 
anti-TB treatment: capreomycin, kanamycin and amikacin” (157). 
 
Unfortunately, XDR-TB strains with adittional second-line drug resistance had also been 
found. Some of these strains are resistant to all the tested antituberculosis antibiotics (63, 
101, 107).  New terms like “extremely drug resistant” (“XXDR-TB”), “super XDR-TB” and 
“totally drug-resistant TB” (“TDR-TB”) were used to define such resistance patterns 
 
New drugs for tuberculosis 
Tuberculosis mismanagement has led to the increasing prevalence of multidrug-resistant 
and even extensively resistant forms of TB. There is now a worldwide recognition that new 
drugs for TB are urgently required, especially with the aims of shortening the treatment, 
and treating MDR-TB and latent infections. A great effort is being done in this direction by 
academic laboratories, non-profit organizations and pharmaceutical companies. 
 
Thanks to research in drug development, a few novel compounds are being generated. 
WHO data show several compounds in early and late clinical trials, including TB 
Oxazolidinone PNU-100480 (Pfizer) and TBK-613-Quinolone (TB Alliance) in advanced 
preclinical trials; Diamine SQ-109 (Sequella Inc.), Linezolid (CDC TBTC, Pfizer, various 
Universities), Pyrrole LL-3858 (Lupin Pharmaceutical Inc.), Diarylquinoline TMC207 
(Tibotec), Nitro-dihydro-imidazooxazole OPC-67683 (Otsuka Pharmaceutical Co.), 
Nitroimidazole-oxazine PA-824 (TB Alliance), Rifapentine (CDC TBTC, sanofi-aventis) in 
clinical phase I and II; and Gatifloxacin (OFLOTUB Consortium, European Commission, 
Lupin, WHO TDR) and Moxifloxacin (TB Alliance, Bayer, CDC TBTC, Johns Hopkins Univ, 
BMRC, UCL) in clinical phase III (158). 
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However, there is still a need to increase the number of drug candidates. A perservering 
research activity in search for new targets and new compounds is being carried out. New 
drugs should target new pathways or enzymes to avoid cross- resistance to existing drugs. 
The targets have to be “druggable” proteins, with ability of inhibition by a small drug-like 
molecule. It is also important that the crystal structure is known or at least that it is 
homologue to other known proteins. In addition, the biochemical activity and biological 
function of the protein has to be understood, as well as what is the metabolic pathway 
that is going to be interfered. 
Transport across the cell envelope of Bacteria 
 
Non-polar compounds can diffuse through phospholipid bilayers, being the permeability of 
a particular membrane directly related with its fluidity.  
 
Regarding mycobacteria, differential scanning calorimetry showed that the lipids in 
mycobacterial cell walls have very high phase transition temperatures, in the range of 60-
70ºC, thus indicating the extremely low fluidity of the lipid bilayer, mainly determined by 
mycolic acids (59). In consequence, due to the high impermeability of the lipid bilayer of 
the mycobacterial membranes even for hydrophobic molecules, it is necessary the 
presence of channels and transporters that make possible the uptake of nutrients and 
efflux of toxic compounds to the outside of bacteria.  
 
Fig 7. The development pipeline for new drugs (2011).  (110) 
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Passive transport: Porins  
These proteins are located in the outer membrane of Gram negative bacteria and the 
outer layer of mycobacteria (35). They are water-filled pores through which hydrophilic 
molecules can enter the bacteria down the concentration gradient. The first porin was 
discovered in E. coli. In mycobacteria, M. smegmatis is known to have several porins, from 
which MspA represents a 70% of all pores (29). M. tuberculosis has also a pore-forming 
protein, OmpATb; however, its role as a porin is unclear (68). 
 
Porins consist of transmembrane antiparallel ß-strands with alternating hydrophobic amino 
acids (facing outwards) and hydrophilic amino acids (facing inwards) assembled into ß-
barrels. Connecting these ß-strands there are short periplasmic turns and longer 
extracellular loops. The electrostatic field resulting from hydrophilic amino acids in the ß-
strands and some extracellular loops, along with the size of the pore, will determine the 
selectivity of the transported molecules (35). 
 
These channels are known to have diverse functions, such as acting as receptors for 
bacteriocins, bacteriophages and elements of the immune system, but the main function 
of porins is to allow the diffusion of hydrophilic molecules into the cell. Many antibiotic 
molecules have low rates of diffusion through porins due to the fact that their sizes are 
similar to the exclusion limit; thus, limiting the uptake of antibiotics, porins contribute to 
intrinsic resistance (35).  
 
Active transport: Transporters 
Transporters are integral membrane proteins that transport molecules across the lipid 
bilayer against the electrochemical gradient. On the basis of bioenergetic and structural 
criteria, transporters can be classified in different groups. Attending to the source of 
energy, these proteins are classified in primary or secondary transporters. Primary 
transporters utilize ATP-hydrolysis whereas secondary transporters use transmembrane 
electrochemical gradient of protons or sodium ions (79).  
Depending on the similarities in primary and secondary structure, transporters can be 
divided into five families, detailed in the following section. 
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Families of Transporters 
ATP-­‐Binding	  Cassette	  Superfamily	  (ABC)	  
ABC proteins are primary transporters implicated both in uptake and efflux. Its an ancient 
family, present in all living organisms. Their substrate profile includes sugars, amino acids, 
ions, drugs, polysaccharides and proteins.  
 
These systems can be encoded by one or more genes, and they are formed by two 
transmembrane binding domains and two nucleotide binding domains. The TMD parts of 
the transporter form the transport channel and consist of a variable number (from 8 to 20) 
of membrane-spanning alpha-helices. The nucleotide binding domains are highly conserved 
among the ABC family; they bind and hydrolyse ATP, powering transport (67). 
Several ABC transporters have been described to be involved in antibiotic resistance, such 
as MacAB-TolC in E.coli, or Rv2686c-Rv2688c in M. tuberculosis (35). 
Major	  Facilitator	  Superfamily	  (MFS)	  
This ancient family of transporters can be found from bacteria to higher eukaryotes. The 
major facilitator superfamily (MFS) is the largest known superfamily of secondary carriers; 
74 families have been described (84). MFS proteins can be divided depending on their 
topology in two major clusters: 12 TMS or 14 TMS (79). At the level of the superfamily, 
individual MFS members share low sequence similarity, having only by a pair of conserved 
signature sequences, whereas homology is higher among members of the same subfamily. 
Nontheless, it has been reported that, despite having low identity in primary sequences, 
all the cristalysed MFS proteins have almost the same 3D structure with two domains 
forming the substrate-translocation pore (56).  
 
They are involved in the symport, antiport, or uniport of different substrates, such as 
monosaccharides, oligosaccharides, amino acids, peptides, phosphate esters, organic and 
inorganic ions and antibiotics (84). NorA of Staphylococcus aureus and MdfA from E. coli 
are some examples of this family of transporters (58). 
 
All MFS transporters involved in antibiotic efflux are drug/proton antiporters (35) and they 
are thought to function as monomers (58). In Gram-negative bacteria, some MFS efflux 
systems can function as components of tripartite systems with MFPs and OM channels (e.g., 
EmrAB-TolC and EmrKY-TolC of E. coli), which can extrude substrates directly to the outside 
of bacteria (58). Other MFS proteins are single-component, so that they export drugs only 
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into periplasm. These drugs can be further taken up by the tripartite RND pumps, which 
will transport them accross the outer membrane (58, 97) .  
Resistance-­‐Nodulation-­‐Cell	  Division	  Superfamily	  (RND)	  
One of the most relevant families of transporters in the clinical context is the RND family, 
which has been characterized best in Gram-negative bacteria (69). These pumps consist of 
three elements: an inner membrane pump protein with 12 transmembrane regions and two 
large periplasmic loops, a so-called membrane fusion protein, and an outer membrane 
protein that forms a channel-tunnel. The pump protein is usually trimeric and appears to 
work in a rotatory fashion in which individual subunits become alternately protonated and 
then engage and subsequently disengage substrate molecules, possibly capturing them 
from the cytoplasmic membrane-periplasm interface. The substrates of RND pumps are 
very diverse and comprise antibiotics, biocides, toxic fatty acids, bile salts, aromatic 
hydrocarbons, inhibitors of fatty acid biosynthesis, detergents, homoserine lactones, and 
dyes. The function of the so-called membrane fusion protein is not well understood but is 
thought to operate as a grappling hook to bring the base of the outer membrane channel-
tunnel into alignment with the inner membrane pump. The outer membrane channel 
comprises a trimeric arrangement of a 12-stranded ß-barrel with very long coiled-coil 
alpha-helical segments on the periplasmic side which at their base contact the pump and 
are thought to open and close at the base through an iris diaphragm-like uncoiling. 
 
Almost all RND systems are able to pump out multiple antibiotics and couple this drug 
efflux with proton antiport. The two best-characterized RND pumps are AcrAB-TolC of E. 
coli and MexAB-OprM of P. aeruginosa. However, there are numerous examples of RND 
efflux pumps with a demonstrated role in antibiotic resistance (35). 
Small	  Multidrug	  Resistance	  family	  (SMR)	  
Members of the SMR family are integral inner membrane proteins from 100 to 140 amino 
acids in length. Each one of these proteins contains 4 TMD, and they form oligomers 
(dimers, trimers and tetramers) to constitute the functional transporter (10). EmrE of E. 
coli is known to function as a dimer, however, the orientation of each protomer remains 
unclear (58). 
 
The SMR family can be divided into three subclasses: the small multidrug pumps, the 
paired SMR proteins, and suppressors of groEL mutant proteins. At a family level, SMR 
proteins have conserved sequences both in TMD1 and TMD4. The remaining TMDs also have 
consensus motifs, but they are related to a subgroup rather than the whole family. (10, 58) 
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They are proton driven, and transport quaternary ammonium compounds, commonly used 
disifectants and detergents and some antibiotics, such us aminoglycosides (10, 58). As MFS 
transporters, in Gram-negative bacteria, compounds can be transported by the SMR protein 
to the periplasm, and further taken by a RND efflux pump which will extrude them to the 
outside of the cell (97).  
Multidrug	  and	  Toxic	  Compound	  Extrusion	  (MATE)	  
Transporters of MATE family have similar topology with MFS proteins, with 12 TMD. 
However, they constitute a different group due to the low homology at the amino acid 
sequence level (35). These proteins function as antiporters, most of them powered by Na+ 
gradient, although some of the use the proton gradient (55), and their substrates include 
fluoroquinolones, aminoglycosides, and cationic dyes (35). The MATE efflux transporters 
are believed to be universally present in all living organisms (55). The first member of this 
family was NorM of Vibrio parahaemolyticus and  other examples are YdhE from E. coli or 
PmpM from Pseudomonas aeruginosa (55). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
More information about drug efflux transporters from mycobacteria and E. coli will be 
detailed in chapters 1 and 3, respectively. 
  
Fig. 8. Schematic representation of efflux pumps in Gram-positive and 
Gram-negative bacteria. Adapted from (78) 
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Role of MFS proteins in Drug Resistance and 
Virulence of M. tuberculosis 
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Introduction 
 
Efflux pumps in mycobacteria have important roles 
Drug-resistance 
To prevent the intracellular accumulation of toxic compounds, bacteria have evolved 
energy-dependent systems to pump such molecules out of the cell. In mycobacteria, most 
of the drug resistant isolates have arisen through the acquisition of chromosomal 
mutations in genes encoding either drug targets or the drug activating enzymes (86), which 
usually confer high-levels of resistance. There are also a significant number of low-level 
drug resistant strains in which no mutation can be found. In these strains, the resistance 
phenotype can be explained in several ways: there could be mutations in other not yet 
discovered drug targets, alteration in the permeability of the cell envelope, or the 
resistance phenotype could be a consequence of the involvement of drug transporters, as 
it has been widely described for other bacterial genera (74). 
 
Virulence 
Transporters play an essential role in the expression of the virulence phenotype in 
bacteria. For example, AcrAB-TolC from Salmonella enterica serovar Typhimurium (22); 
regarding M. tuberculosis, the RND efflux pumps MmpL4, MmpL7, MmpL8 and MmpL10 are 
known to contribute to virulence (32, 37), as well as the ABC efflux pump DrrABC (23, 37). 
 
Efflux pumps object of study 
Rv1258c (Tap) 
This efflux pump from M. tuberculosis, belonging to MFS, has 12 TMS (Fig 8). Rv1258c 
orthologue was first described in Mycobacterium fortuitum, a fast-growing mycobacteria 
causing diverse infections in humans as an efflux pump mediating low-level resistance to 
tetracycline, streptomycin, gentamicin and other aminoglycosides (3). The M. tuberculosis 
Rv1258c was characterised in heterologous hosts (M. bovis BCG and M. smegmatis mc2155), 
showing a rather similar behaviour (3, 30, 82) . It was also observed that disruption of the 
Rv1258c-orthologue in the vaccine strain M. bovis BCG resulted in alterations in the growth 
kinetics (82).  Other groups have revealed that this gene could be overexpressed in multi-
drug resistant clinical isolates of M. tuberculosis and that its expression depends on the 
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transcription factor whiB7 (65). Besides, Rv1258c has been reported to be conferring 
rifampicin tolerance upon macrophage infection (1). 
 
 
 
 
 
Rv1410c (P55) 
This efflux pump, a MFS protein with 12 TMS (Fig. 9) was first identified as the product of a 
gene downstream of that encoding the antigenic lipoprotein P27 from pathogenic M. bovis 
isolates in a two-gene operon (15, 16). Rv1410c efflux pump from M. tuberculosis was 
primarily characterised in the heterologous hosts M. smegmatis mc2155 (90) and M. bovis 
BCG (81) and identified some of their drug-substrates, among which the antituberculous 
drug rifampicin seems to increase the expression of this gene in M. bovis BCG (following 
our results using lacZ as a reporter gene); in the latter microorganism, its inactivation also 
produced alterations in colony and bacillus morphology (82). A recent study clearly 
indicated that P27 (Rv1411c) and Rv1410c are functionally connected in processes that 
involve the preservation of the cell wall and the transport of toxic compounds away from 
the cells (11). Almost simultaneously, two groups described that insertional inactivation of 
the upstream P27 gene resulted in strong attenuation of M. tuberculosis (17, 87); the first 
group also found a similar phenotype for the insertional inactivation of Rv1410c. 
 
Fig .8. Prediction of TMS of Rv1258c efflux pump, using Hidden Markov Models 
(http://www.cbs.dtu.dk/services/TMHMM/) 
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Rv2333c (Stp) 
It has been previously described the contribution of the Rv2333c efflux pump to intrinsic 
tetracycline and spectinomycin resistance of M. bovis BCG (80) where the inactivation of 
the gene resulted also in a slower growth rate in liquid media. Other group identified that 
the M. tuberculosis Rv2333c gene increased it expression by more than 10 times upon 
infection of human macrophages (25). Rv2333c protein belongs to the MFS Superfamily, 
and it has 14 TMS (Fig 10). 
 
 
 
Fig .9. Prediction of TMS of Rv1410c efflux pump, using Hidden Markov Models 
(http://www.cbs.dtu.dk/services/TMHMM/) 
 
Fig. 10. Prediction of TMS of Rv1410c efflux pump, using Hidden Markov Models 
(http://www.cbs.dtu.dk/services/TMHMM/) 
 
 48 
Genetic tools for generating knock-out strains in M. tuberculosis 
The RecA protein was the first recombination enzyme to be identified in M. tuberculosis. 
As in E. coli, expression of M. tuberculosis RecA is associated with the SOS response that is 
triggered by DNA damage. Allelic exchange, or gene knockout, is an essential tool to 
investigate gene function in bacteria. It is usually achieved through the operation of 
homologous recombination systems to replace the target copy of the gene in the 
chromosome with an inactive copy of the gene located on a vector (88).  
 
Initial attempts to achieve allele replacement in M. tuberculosis were frustrated by the 
high levels of illegitimate recombination in the pathogen (48). Numerous strategies have 
been devised to obtain efficient allele replacement in M. tuberculosis. Most experiments 
have utilized a plasmid delivery system, although phage systems have also been employed 
(73, 92). Most recently, a “recombineering” method was developed; it’s based on the 
inducible expression of mycobacteriophage recombinases that enhance the frequency of 
recombination so that a linear fragment of DNA can recombinate in a single step (104).  
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OBJECTIVES 
 
- To construct a knock-out, a complemented and an overexpression strain, derived 
from H37Rv virulent strain, for each of the efflux pump genes Rv1258c, Rv1410c 
and Rv2333c. 
 
- To find if these efflux pump genes are implicated in intrinsic drug resistance of M. 
tuberculosis. 
 
- To perform infection assays with these strains with the aim of finding a possible 
role of M. tuberculosis in virulence. 
 
  
 50 
Material and Methods 
Bacterial strains, media and growth conditions 
In this work, we have used M. tuberculosis H37Rv and E. coli XL1, and E. coli DH5α. 
 
E. coli strains were cultured in Luria-Bertani (LB) broth or on LB agar plates at 37ºC. 
Antibiotics were added when necessary, at final concentrations listed in Table 3.  Liquid 
cultures were grown in glass tubes in a shaker. 
 
Cultures and all manipulations of M. tuberculosis were done in a Biosafety Level 3 
Laboratory (BSL3).  
 
M. tuberculosis was cultured in Middlebrook 7H9 liquid medium supplemented with 10% 
ADC (0.5% bovine serum albumin, 0.2% dextrose, 0.085% NaCl, 0.0003% beef catalase) 
(Difco) (7H9/ADC from now). In order to keep the culture clump-free, Tween 80 was added 
to a final concentration of 0,05%, except for the media used in susceptibility assays and 
cultures for lipid extraction, which were supplemented with glycerol 0.5%. 
 
Solid medium was Middlebrook 7H10 agar supplemented either with 10% ADC (7H10/ADC 
from now) or 10% OADC (0.05% oleic acid, 0.5% bovine serum albumin, 0.2% dextrose, 
0.085% NaCl, 0.0003% beef catalase) (Difco) (7H10/OADC from now).  
 
M. tuberculosis H37Rv and derivatives were grown at 37ºc; liquid cultures were done in 
cell culture flasks, without shaking. 
 
Antibiotics, X-Gal (5-bromo-4-chloro-indolyl-β-D-galactopyranoside) and sucrose were 
added when necessary at final concentrations listed in table 3. X-Gal was used to visualize 
the expression of the reporter gene lacZ, whereas sucrose was used for the 
counterselection of bacteria containing vectors carrying sacB gene.  
 
Storage of strains was done at -80ºC in presence of 15% glycerol. 
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Compound E. coli M. tuberculosis 
Kanamycin (Km) 20 µg/ml 20 µg/ml 
Tetracyclin (Tet) 10 µg/ml - 
Hygromycin (Hyg) 50 µg/ml 50 µg/ml 
X-GAL 64 µg/ml 64 µg/ml 
Sucrose  - 2% (w/v) 
General techniques of nucleic acids 
DNA extraction 
Genomic DNA extraction of mycobacteria 
For DNA extraction the CTAB method was used (105). 1.5 ml of liquid culture was 
centrifuged (12000 rpm, 5 min) and the pellet resuspended in 400 µl of TE. This was 
heated for 10 min at 85ºC to inactivate the bacteria and 50µl of lysozyme 10mg/ml were 
added and incubated for minimum of 1 hour (but normally overnight) at 37ºC. 
Subsequently, 75 µl of the Prot K/SDS mix was added to each sample, and the suspension 
warmed for 10 min at 65ºC. After this, 100 µl of NaCl 5M and 100 µl of CTAB/NaCl pre 
warmed at 65ºC were added and samples incubated for further 10 min at 65ºC. Genomic 
DNA was extracted by adding 0.75 ml of chloroform:isoamyl alcohol 24:1. Samples were 
mixed by vortexing for 10 s before centrifugation (13000 rpm, 5 min). The aqueous phase 
was transferred to a fresh tube containing 420 µl of cold isopropanol, and samples were 
precipitated at -20ºC for at least 30 min. Nucleic acids were collected by centrifugation 
(13000 rpm, 10 min) and the pellets washed with 1 ml of cold EtOH 70%. After 
centrifugation (13000, 5 min) the pellet was vacuum dried, dissolved in 40 µl of double 
distilled water and treated with  1 µl of RNAse 1 mg/ml for 15 min. DNA was storaged at -
20ºC. 
 
DNA was quantified by absorbance readings at 260nm using a ND-1000 spectrophotometer 
(NanoDrop technologies). 
 
Reagents & Solutions 
CTAB/NaCl: 10% CTAB in 0.7 M NaCl 
Prot K/SDS: 72.5 µl of SDS 10% + 2,5 µl Proteinase K 20 mg/ml 
TE: 10 mM Tris HCl, 1 mM EDTA, pH8 
 
Table 3. Antibiotics and other compounds used in this work. 
 
 52 
Fast mycobacterial DNA extraction for PCR 
This method releases plasmidic and genomic DNA from mycobacteria, usually in enough 
quantity to detect the presence of target genes by PCR. 500µl of liquid culture were 
centrifuged (12000 rpm, 5 min) and pellet resuspended in 400 µl TE. Alternatively, a 
colony can be disgregated in 400 µl TE. The bacterial suspensions were inactivated by 
heating at 90ºC for 30 min. After centrifugation (12000 rpm, 10 min), 350 µl of supernatant 
were transferred to a fresh tube and mixed with 350µl of chloroform:isoamyl alcohol 24:1 
by vortexing for 10-20 sec. After centrifugation (12000 rpm, 5 min) the aqueous phase was 
transferred to a fresh tube; typically 2µl of this DNA solution were used in a standard PCR 
reaction. 
Plasmid DNA extraction from Escherichia coli 
Mini-­‐preparation	  (Mini-­‐prep)	  
1.5 ml of a liquid culture grown overnight were centrifuged (12000 rpm 15 min) and the 
pellet resuspended in 100 µl of Solution I. 200 µl of freshly made Solution II were added, 
and the content mixed by inverting the tube several times, until it becomes transparent 
and viscous. After incubation on ice for 5 min, 150 µl of cold Solution III were added and 
the tubes were mixed by inversion; as a result, a white pellet is formed. This mix was 
incubated on ice for 5 min, followed by centrifugation (12000 rpm 10 min). Supernatants 
were then transferred to a fresh tube and mixed with the same volumen of 
chloroform:isoamyl alcohol 24:1. After centrifugation, the aqueous phase was transferred 
to a tube containing 900 µl EtOH and 50 µl NaAc 3M and incubated at -20ºC for 30 min. By 
centrifugation (12000 rpm 5 min) small nucleic acids (plasmids and tRNA) were pelleted, 
and then washed with 100 µl EtOH 70%. Finally, the pellet was vacuum dried and 
resuspended in 20 µl double distilled water. RNA, which co-purifies with plasmidic DNA, 
was removed by adding 1 µl RNAse 1 mg/ml and incubating for 15 min at 37ºC. Plasmidic 
DNA was kept at -20ºC. 
Reagents & Solutions 
Solution I: 50 mM glucose, 10 mM EDTA, 25 mM Tris HCl pH8 
Solution II: 0,2 M NaOH, 1% SDS 
Solution III: 5 M NaAc, 11,5% Glacial HAc 
TE: 10 mM Tris HCl, 1 mM EDTA, pH8  
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Maxi-preparation (Maxi-prep) 
This method was used to obtain large quantities of plasmid. The process is the same as the 
mini-preparation, but starting with 100 ml of liquid culture. Larger volumes of solutions 
are needed: 5 ml Solution I, 10 ml Solution II and 7,5 ml Solution III. Besides, precipitation 
of plasmid DNA is done with isopropanol instead of ethanol. Finally, nucleic acids are 
disolved in 250 µl of double distilled water and treated with 10 µl RNase 1 mg/ml for 15 
min at 37ºC.  
 
Construction of plasmids 
DNA fragments for cloning purposes were amplified by PCR using the Pwo high fidelity DNA 
polymerase (Roche), and gel-purified by using QIAquick Gel Extraction Kit (Qiagen). 
Plasmids were cut by restriction endonucleases and gel-purified by using QIAquick Gel 
Extraction Kit (Qiagen). Ligations were done using T4 DNA ligase (Invitrogen). 
Construction of the replicative plasmid pCVZ1 
A 3127 bp DNA fragment containing the operon Rv1411c-P55 from M. tuberculosis H37Rv 
was amplified by PCR with oligonucleotides P55-C1 and P55-C2. This PCR fragment was 
digested with the restriction enzymes BglII and HindIII and inserted into pSUM36 replicative 
vector digested with BamHI and HindIII. To confirm the absence of PCR-induced mutations 
in the final plasmid pCVZ1 (Fig. 11), it was sequenced using the oligonucleotides M13Fw, 
M13Rv, cp55-1, cp55-2, p55-trans-in and vec19-up (Table 5). 
 
 
Fig 11. Replicative plasmid pSUM36 and its derivative, pCVZ1, carrying M. tuberculosis H37Rv Rv1411c and 
P55 genes.  
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Construction of the integrative plasmids pCRS2, pCRS3 and pCRS4 
All these plasmids were cloned in pMV361 vector, which has a multiple cloning site after 
the strong promoter PHsp60. During the cloning, we eliminated part of the PHsp60 promoter by 
removing the fragment AclI-HindIII of pMV361, then allowing the expression of the cloned 
genes under control of their own promoters. 
 
In order to generate pCRS2 (Fig. 12), a 2494 bp DNA fragment containing Rv2333c (stp) 
gene from M. tuberculosis H37Rv was amplified by PCR with oligonucleotides Spt-C2 and 
Spt-C3. This PCR fragment was digested with restriction enzymes AclI and HindIII and 
inserted into pMV361 integrative vector digested with AclI and HindIII. The resulting 
plasmid was sequenced with oligonucleotides pMV361A, pMV361B, 2333-1F, 2333-1R, cspt1 
and cspt2 (Table 5) to verify the sequence. 
 
The plasmid pCRS4 (Fig. 12) was constructed by cloning Rv1258c (tap) gene from M. 
tuberculosis H37Rv into pMV361 vector. First, a 2201 bp DNA fragment containing tap gene 
was amplified by PCR with Tap-C2 and Tap-C3 oligonucleotides (Table 5). Following 
digestion of this PCR product with restriction enzymes, it was inserted in pMV361 vector 
previously linearized with AclI and HindIII. Sequences obtained with oligonucleotides 
pMV361A, pMV361B, ctap5, ctap6, ctap7 and ctap8 were analysed to confirm the absence 
of mutations in the insert. 
 
Plasmid pCRS3 (Fig. 12), carrying the operon Rv1411c-P55 from M. tuberculosis H37Rv was 
generated in two steps. First, the fragment AclI-PvuII, containing part of PHsp60, was 
removed by digesting with restriction enzymes AclI and PvuII;  the linearized vector was 
then treated with T4 DNA polymerase and recircularized, yielding pMVD361 (Fig. 12). 
 
The second step consisted of an amplification of a 3127 bp DNA fragment containing the 
operon Rv1411c-P55 from by PCR with primers P55-C2 and P55-C4, followed by digestion 
with the restriction enzymes EcoRI and HindIII. This fragment  was inserted in pMVD361, 
also digested with EcoRI and HindIII, resulting in the plasmid pCRS3. Absence of mutations 
in the insert were checked by sequencing performed with oligonucleotides: pMV361A, 
pMV361B, cp55-1, cp55-2, p55-trans-in and vec19-up (Table 5). 
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A 
B 
Fig 12. Integrative plasmid pMV361 and its derivatives. A. Vector pMV361 B. Plasmids pCRS2 and 
pCRS4 carrying stp and tap genes from M. tuberculosis H37Rv, respectively. C. Integrative plasmid 
pMVD361 and its derivative pCRS3, containing Rv1411c and P55 genes from M. tuberculosis H37Rv. 
C 
 56 
These plasmids, along with the plasmids previously constructed by our group, are listed in 
Table 4. 
Replicative plasmids 
Plasmid Marker genes Description Ref. 
pSUM36 KmR (Tn5- derived) 
Shuttle vector E. coli/mycobacteria for expressing 
genes in mycobacteria. 
(4) 
pPAZ11 KmR (Tn5- derived) 
pSUM36 derived plasmid with Rv1258c (tap) gene 
under control of its own promoter. 
(82) 
pSAN17 KmR (Tn5- derived) 
pSUM36 derived plasmid with Rv2333c (stp) gene 
under control of its own promoter. 
(80) 
pCVZ1 KmR (Tn5- derived) 
pSUM36 derived plasmid with Rv1410c (P55) 
gene under control of its own promoter. 
This 
work 
Suicide plasmids 
Plasmid Marker genes Description Ref. 
pVZ17 
HygR, KmR (Tn903-
derived), PAg85-sacB, 
PHsp60-lacZ 
p2NIL/pGOAL derived plasmid, containing 
Rv1258c (tap) gene disrupted by a HygR marker 
(82) 
pILI9 
HygR, KmR (Tn903-
derived), PAg85-sacB, 
PHsp60-lacZ 
p2NIL/pGOAL derived plasmid, containing 
Rv2333c (stp) gene disrupted by a HygR marker 
 
pILI12 
HygR, KmR (Tn903-
derived), PAg85-sacB, 
PHsp60-lacZ 
p2NIL/pGOAL derived plasmid, containing 
Rv1410c (P55) gene disrupted by a HygR marker 
(81) 
Integrative plasmids 
Plasmid Marker genes Description Ref. 
pMV361 KmR (Tn903-derived) 
Integrative vector, for expressing genes under 
control of Hsp60 promoter 
(95) 
pCRS4 KmR (Tn903-derived) 
pMV361 derived plasmid, containing Rv1258c 
(tap) gene under control of its own promoter. 
This 
work 
pCRS2 KmR (Tn903-derived) 
pMV361 derived plasmid, containing Rv2333c 
(stp) gene under control of its own promoter. 
This 
work 
pMVD361 KmR (Tn903-derived) pMV361 derived, lacking AclI-PvuII fragment 
This 
work 
pCRS3 KmR (Tn903-derived) 
pMVD361 derived plasmid, containing Rv1410c 
(P55) gene under control of its own promoter. 
This 
work 
 
Table 4. Plasmids used in this study.   
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Oligonucleotides 
All the oligonucleotides are listed in Table 5. Artificial endonuclease restriction sites were 
added when required and are shown underlined. 
 
Oligonucleotide Sequence 5’->3’ Description 
2333-1F GACGGCCTGCAGTGGGTG Sequencing pCRS2 
2333-1R CATGGCGACGGTCGTGATC Sequencing pCRS2 
2333-B CCAGTGGAATTCGACGAAAC To verify stp knock-out mutants.Sequencing. 
2333-med TCTGACCCTGTTCCGCG To verify stp knock-out mutants.Sequencing. 
cp55-1 TTGCTCACATGTTCTTTCCTG Sequencing P55 gene 
cp55-2 CGACGGCAAACACGTACTG Sequencing P55 gene 
cspt1 GGTGAGCACCGCGATTG Sequencing pCRS2 
cspt2 GTTCCTGCAGAACGTGCG Sequencing pCRS2 
ctap5 GTCGACTACTTCGGGCGTC To verify tap knock-out mutants.Sequencing. 
ctap6 GACCATCGATGCCAAACC To verify tap knock-out mutants.Sequencing. 
ctap7 GTCCAACGACCAGCCTGC Sequencing tap gene. 
ctap8 CGCTGTATCTGCCGATGG Sequencing tap gene. 
Hyg-out TGATCCGGTGGATGACC To verify knock-out mutants 
Km903-A CTCGTGAAGAAGGTGTTGCT To confirm presence of Km
R Tn903- derived 
gene 
Km903-B CCGACCATCAAGCATTTTAT To confirm presence of Km
R Tn903- derived 
gene 
M13Fw GTAAAACGACGGCCAGT To sequence pSUM36 and derivatives 
M13Rv AGCGGATAACAATTTCACAC To sequence pSUM36 and derivatives 
P55 trans-in ACGCCCTGGCCGAACAGC To verify P55 knock-out mutants.Sequencing. 
P55-C1 TTTTAGATCTTTCACCGGTGGCGTCC To clone P55 gene in pSUM36. BglII site underlined. 
P55-C2 TTTTAAGCTTCTTGGTCGGCACCGGC To clone P55 gene in pSUM36 and pMVD361. HindIII site underlined. 
P55-C4 TTTTGAATTCTTTCACCGGTGGCGTCC To clone P55 gene in pMVD361 EcoRI site underlined. 
p55-out1 GGATGACCGGCATGTTGATC To confirm presence of pCRS3 
pks3-Fw CGCTGACGTCGGTGAAAAC To sequence position 1467 of pks3 gene 
pks3-Rv CTGCACCCGGTCAATACC To sequence position 1467 of pks3 gene 
pMV361-A CAGGAGCATTGCCGTTCC Sequencing pMV361 and derivatives 
pMV361-B CCTCGAGCAAGACGTTTCC Sequencing pMV361 and derivatives 
RP-180 ATGCAGCTGGCACGACAGGT To verify replicative plasmids derived from pSUM36. 
Spt-C2 CCAACAACGTTTTGGCGTTTCC To clone stp gene in pMV361. AclI site underlined. 
Spt-C3 CTGCAGCCAAGCTTGCATGCC To clone stp gene in pMV361. HindIII site underlined. 
spt-out1 CCAGTGGCGATGAGCGTGAG To confirm presence of pSAN17and pCRS2 
Tap-C2 TTTTAACGTTGCCCGGGGGCGCAC To clone tap gene in pMV361 AclI site underlined. 
Tap-C3 TTTTAAGCTTGTACAGGCCGGGCTGGC To clone tap gene in pMV361 HindIII site underlined. 
tap-out1 CAGCGTTGCGAACAGGATCAG To confirm presence of pPAZ11 and pCRS4 
TN5-A CGCTTGGGTGGAGAGGCTATTC To confirm presence of Km
R Tn5- derived 
gene 
TN5-B CCGCTCAGAAGAACTCGTCAAG To confirm presence of Km
R Tn5- derived 
gene 
vec19-up AGCAGGACGTCGAGTCGCG To verify P55 knock-out mutants.Sequencing. 
 
Table 5. Oligonucleotides used in this study. 
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Southern Blot 
Approximately 3 µg of extracted genomic DNA were digested with PvuII or PstI (see table 
x). The fragments were separated by electrophoresis through 0.8% agarose gels in Tris- 
Borate-EDTA (TBE) buffer for 18h at 36V. After migration, a standard treatment of the gel 
was performed. DNA was fixed by UV light for 5min and subjected to a depurination 
treatment (0.25M HCl for 10min), washing, denaturalization (0.5M NaOH, 1.5M NaCl for 
20min) and neutralization (1.5M NaCl, 1M Tris, pH=8.0 for 20min). Hereafter, DNA was 
vacuum blotted (45-60mbar for 1h 30min) onto a Hybond-N+ nylon membrane (Amersham) 
using 10x SSC buffer (1.5M NaCl, 150mM sodium citrate). Blotted DNA was fixed by UV light 
for 4 min and hybridized with a specific probe. This probe was made by PCR with Taq Gold 
polymerase (Applied Biosystems) using specific oligonucleotides (Table 6). This PCR 
product was then purified using GFXTM PCR kit and adjusted to 10 ng/µl. After labeling the 
probe, hybridization patterns were visualized using ECLTM Direct Nucleic Acid Labelling 
and Detection System (Amersham). 
 
Generation of competent cells & electroporation 
E. coli 
To prepare electrocompetent cells, 300 ml of a  bacterial culture were grown to an OD600nm 
of 0.4 - 0.6. Then the growth was stopped for 30 min on ice, and bacteria were washed 
twice in chilled-cold water, and once in chilled-cold 10% glycerol. Cells are finally 
resuspended in 1 ml chilled-cold 10% glycerol. Aliquots of 40 µl can be storaged at -80ºC 
for further use. 
 
Aliquots of 40 µl were electroporated with ~100 ng purified plasmid DNA in 0.2 cm gap 
cuvettes (Bio-Rad) with a single pulse (2.5kV, 25µF, 200Ω) in a GenePulser XcellTM (Bio-
Rad). Cells were resuspended in LB to a final volume of 1 ml and incubated for 1h at 37ºC 
M. tuberculosis 
H37Rv deleted gene 
DNA digested 
with 
Probe 
PCR with oligonucleotides Size 
Rv1258c PstI ctap5 vs ctap6 0,7 Kb 
Rv2333c PvuII 2333-med vs 2333-B 1,1 Kb 
Rv1410c PvuII p55-trans-in vs vec19-up 0,9 Kb 
Table 6. Restriction enzymes used for digesting genomic DNA and construction of specific probes for Southern 
Blot. 
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before plating several dilutions on plates containing the needed antiobiotic. Colonies 
appeared after incubation overnight. 
 
M. tuberculosis 
M. tuberculosis competent cells were prepared as described by Wards et al. (108). 200 ml 
of bacterial culture were grown to an OD600nm of 0.6-0.8. 24 h before preparing the 
competent cells, glycine was added to the cells to a final concentration of 0,2 M and 
incubated at 37ºC.  
 
All the process was performed at room temperature. Bacterial pellet was washed twice 
with 0.05% Tween- 80 and once with 10% glycerol-0.05% Tween-80, and finally resuspended 
in 2ml of 10% glycerol-0.05% Tween-80. Aliquots of 200-400 µl of competent cells can be 
storaged at -80ºC for further use. 
 
Aliquots of 200-400µl were electroporated with 100-200 ng of replicative or integrative 
plasmid DNA (previously purified), using 0.2 cm gap cuvettes (Bio-Rad) with a single pulse 
(2.5kV, 25µF, 1000Ω) in a GenePulser XcellTM (Bio-Rad). Cells were recovered with 1ml of 
7H9-ADC-0.05% Tween-80 and incubated for 24h at 37ºC, to express the antibiotic 
resistance genes, before plating serial decimal dilutions on plates containing the relevant 
antibiotic. Colonies typically appeared in 3-4 weeks. 
 
Suicide plasmids 
Electrocompetent cells were prepared the same way, but resuspending in a final volume of 
1,5 ml 10% glycerol-0.05% Tween-80 in order to obtain a denser cell suspension. Fresh 400 
µl aliquots were transformed with 15-20 µg of purified plasmid DNA, which had been 
previously irradiated with UV light (λ=360nm) for 2-10 s. All the transformation mix was 
plated, dividing it in three agar plates. Colonies typically appeared in 4-5 weeks. 
 
Construction of knock-out strains of M. tuberculosis 
Knock-out mutants of M. tuberculosis H37Rv were constructed following the method 
described by Parish et al. (73). A suicide plasmid fulfilling several characteristics is needed 
(Fig 13). 
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This plasmid has the target gene 
disrupted by a Hyg resistance marker, in 
addition to a Km resistance marker and a 
cassette containing the genes lacZ and 
sacB under control of the strong 
promoters PAg85 and Phsp60 respectively. 
Since it lacks an origin of replication for 
mycobacteria, it is a suicide plasmid.	  	  	  
A suicide plasmid derived from pNIL and 
pGOAL series had been previously 
constructed in our group for each target 
gene Rv1258c (pVZ17), Rv2333c (pILI9) 
and Rv1410c (pILI12) (see plasmids).  
 
When this plasmid was electroporated in M. tuberculosis (see Generation of competent 
cells and electroporation, M. tuberculosis, suicide plasmids), a first event of simple 
recombination can take place between the disrupted gene of the plasmid and the wild-
type gene in the genomic DNA resulting in a recombinant strain, named Single Cross Over 
(SXO) mutant. SXO strain has the suicide plasmid integrated in its genomic DNA, so 
mutants are resistant to Hyg and Km, and have a lactose positive phenotype; for this 
reason they were selected in 7H10/ADC supplemented with Hyg, Km and X-Gal. Blue 
colonies (lac+) were candidates for being SXO. Thus, they were inoculated in 7H9/ADC with 
Hyg and Km, and incubated for 10-15 days at 37ºC. Several PCRs were performed to verify 
this first recombination. 
 
In order to induce the second recombination event, several decimal dilutions (10-1, 10-2 and 
10-3) of SXO strain liquid culture were plated on 7H10/ADC supplemented with Hyg, X-Gal 
and sucrose. The marker gene cassette has the counter-selection marker sacB, which is 
lethal for bacteria in the presence of sucrose (75). Thus, SXO mutant wasn’t able to grow 
in the selection medium, except the case when the wild-type and the disrupted genes 
recombinated, removing the plasmid from the genome. This second recombination event 
yielded the Double Cross Over (DXO) mutant, which was the final knock-out strain, with a 
phenotype Hyg and sucrose resistant, Km sensitive and lactose negative. White colonies 
(lac-) were candidates for being DXO strains, so they were inoculated in 7H9/ADC/Hyg and 
cultured for 10-15 days, then checked by PCR and Southern Blot 
P
Ag85
-lacZ,  
P
hsp60
-sacB 
Suicide 
plasmid 
Fig. 13. Scheme of suicide plasmids for 
generating knock-out mutants. 
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Phenotypical characterization of M. tuberculosis 
Growth in liquid medium 
In order to characterize growth in liquid medium, 100 ml of 7H9/Tween/ADC were 
inoculating with 105 cfu/ml, using a culture in logarithmic phase. OD600nm was measured for 
1 month. When OD600 reached 1, the culture was diluted ½ and ¼ and OD corrected 
depending on the dilution.  
 
Neutral Red Stain 
This method was adapted from Soto et al. (93). Mycobacterial strains were grown on 
7H10/ADC medium for 3-4 weeks. Cells were placed and gently disgregated in Falcon 15ml 
tubes containing 4ml of 50% methanol, and then incubated for 1h at 37ºC. Cells were 
pelleted by centrifugation (4000 rpm, 5 min), and methanol removed. Then, 4ml barbital 
buffer were added and the pellet mixed by inversion. Subsequently, 150µl of a solution of 
neutral red were added. Results were evaluated after 1h incubation at 37ºC.  
A. Medium with sucrose 
B. Medium without sucrose 
Fig. 14. Comparison of growth of M. tuberculosis carrying sacB gene in medium 
with and without sucrose. Dilution of the SXO liquid culture is indicated. White 
colonies (lac-) are candidates for DXO mutants, whereas SXO are spontaneous 
mutants resistant to sucrose. 
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Reagents & Solutions 
50% methanol: 50% methanol, 50% distilled water  
Barbital buffer: 1% sodium barbital in 5% NaCl, pH=9.8 
Neutral red: 0,05% neutral red disolved in distilled water.  
 
 
Analysis of lipids of M. tuberculosis cell wall 
Extraction of free lipids and mycolic acids from M. tuberculosis cell wall  
Strains were inoculated in 200 ml 7H9/ADC/0,5% glycerol, it is important not to add Tween 
80 because the free lipids can be partially lost. After approximately one month of 
incubation at 37ºC, cultures were centrifuged (4000 rmp, 20 min) and PBS 1x added to 
wash the cells. Subsequently, cells were pelleted (4000 rpm, 1h) and PBS removed by 
decanting. Pellets can be frozen and storaged at -80ºC or used immediately. 
 
First extraction was performed with chloroform:methanol 1:1. Bacterial pellets were let to 
dry as much as possible before resuspending them in 4 ml methanol. The suspension was 
then transferred to a glass tube with PTFE cap and 4 ml chloroform were added. This mix 
was incubated for 2 days at room temperature, gently shaking occasionally. The organic 
phase containing free lipids was then transferred to a fresh glass tube. 
 
A second extraction was made using 4 ml chloroform:methanol 2:1. The two extracted 
fractions were joined in the same glass tube, and further evaporation of the organic phase 
with a stream of nitrogen gas resulted in dried pellet of lipids.  
 
The remaining bacterial residues were kept to extract mycolic acids. First, 8 ml of 
MeOH:toluene:H2SO4 (30:15:1) were added to the glass tube containing the bacterial 
residues, and heated at 80ºC overnight, vortexing occasionally. In this process the esther 
bond was broken and mycolic acids released as methylic esthers. Two consecutive 
extractions with 8 ml hexane were made, and hexane further evaporated with a stream of 
nitrogen gas. 
 
Thin Layer Chromatography 
Crude extracts and mycolic acids were resuspended in 100 µl and 200 µl chloroform, 
respectively. 10 µl of each extract were deposed on silica gel G60 plates (20x20cm; Merck) 
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and analyzed by thin layer chromatography (TLC). As controls, 10 µl of purified fractions of 
M. tuberculosis cell wall free lipids (2mg/ml) were included. 
 
Different solvents were used depending on the polarity of the lipids we want to separate 
(Table 7). To visualize lipids, several reagents can be used: anthrone for glycolipids, 
Dittmer (molybdenum blue) for phospholipids and molybdophosphoric acid (MPA) for 
general lipids. Plates were sprayed with the chosen reagent and then heated a 110ºC-120ºC 
until coloured spots appeared. 
 
Lipids Eluent (v:v) Reagent 
PAT, DAT, CF, SL-I CHCl3:MeOH 85:15 Anthrone 
PIMs CHCl3:MeOH:H2O 60:35:8 Anthrone 
Phospholipids CHCl3:MeOH:H2O 60:35:8 Dittmer 
PDIM, TG Petroleum ether:diethylether 90:10 PMA 
PGLs CHCl3:MeOH 95:5 Anthrone 
Mycolic acids  Hexane: diethylether 85:15 PMA 
 
 
 
Reagents & Solutions 
Anthrone: 1% anthrone in H2SO4 
Molybdophosphoric acid: molybdophosphoric acid 10% in ethanol 
   
 
Susceptibility assays: Minimum Inhibitory Concentration 
The resazurin assay 
Serial two-fold dilutions of antibiotics were performed in 7H9/glycerol 0,5%/ADC medium, 
in 96-well microtiter plates, with a final volume of 100µl per well.  
 
Liquid cultures of M. tuberculosis in logarithmic phase were adjusted to 105 cfu/ml in 
7H9/glicerol 0,5%/ADC. 100µl of this suspension were added to each well and plates were 
incubated 6 days at 37ºC. 30 µl of resazurin solution were then added to each well, and 
results were observed after 48h of incubation at 37ºC. Resazurin (blue) is an indicator of 
bacterial growth, since metabolic activity of bacteria reduces it to resofurin (pink). 
Table 7. Eluents and Reagents used in TLC for each group of lipids. 
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Minimum Inhibitory Concentration (MIC) is the concentration of antibiotic of the first well 
that doesn’t change color from blue to pink. 
Reagents & Solutions 
Resazurin: 0,1 mg/ml resazurin in distilled water 
 
Infection assays 
Intracellular replication  in J774 mouse macrophages 
Intracellular replication of M. tuberculosis was tested in J774 mouse macrophage-like 
cells. J774 cells were grown in Dulbecco’s modified Eagle medium (DMEM) supplemented 
with 10% fetal bovine serum (FBS) and 4mM L-glutamine (“complete DMEM” from now). 
Infections were performed at a multiplicity of infection (MOI) of 0.5-1 bacteria per 
macrophage, with a variable number of cells per well depending on the experiment. After 
4 h, infection was stopped by removing bacterial suspension and cells were washed three 
times with 1 ml PBS, and finally cultured in 2ml complete DMEM per well to allow 
intracellular replication. Medium was replaced when needed (typically every 1-2 days) by 
removing 1,5 ml of overlaying DMEM and adding the same volume of fresh complete DMEM. 
In order to know the number of intracellular bacteria at the end of time of infection (4h) 
and days 3, 5 and 7 post-infection, DMEM medium was removed, and 300 µl 0.1% triton X-
100 were added to each well in order to lyse the cells. 700 µl of PBS were added per well 
and the solution carefully mixed. Several dilutions of this lysate were plated on 7H10/ADC 
plates and viable bacteria counted after 2-4 weeks. 
 
Apoptosis induction in J774 mouse macrophages 
Apoptosis induction of M. tuberculosis was tested in J774 mouse macrophage-like cells. 
J774 cells were seeded in wells, in complete DMEM. Infections were performed at a 
multiplicity of infection (MOI) of 30-50 bacteria per macrophage, with 105 cells per well. 
After 4 h, infection was stopped by removing bacterial suspension and cells were washed 
three times with 1 ml PBS, and finally cultured in 2ml complete DMEM per well to allow 
intracellular replication.  
 
At day 3 or 4 post-infection, both supernatant and trypsinized cells were collected 
together in 15 ml screw-cup tubes. Phosphatidylserine exposure and membrane integrity 
were analyzed by using Annexin-V and 7-actinomycinD (BD Biosciences) and flow cytometry 
according to manufacturer instructions. Briefly, cells were washed with PBS and incubated 
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with Annexin-V and 7AAD in Annexin-binding buffer for 15 min. After that, cells were 
washed twice with PBS, fixed with 4% paraformaldehyde (PFA) during 30 min and washed 
again with PBS. Both PBS and PFA solutions contained CaCl2 2.5 mM. 
 
Replication in lungs in mouse model 
Intratracheal infection in C57BL/6 mice was performed with 150-300 CFU of bacteria in 
50µl of PBS 1x per mouse and 5 mice were used per strain. To deliver bacterial suspension, 
isoflurane anesthetized mice were orally intubated with a lachrymal olive luer-lock 
(UNIMED), 30mm in length and 0.6mm in diameter. Serial dilutions of the bacterial 
suspension were plated to corroborate the number of viable bacteria. Three weeks post-
infection, lungs from each animal were harvested and placed in PBS for bacterial burden 
evaluation. To analyze bacterial replication, lungs were homogenized using GentleMacs 
homogeneizer (Miltenyi Biotec) and CFU counted by plating serial dilutions on 7H11/ADC 
solid medium supplemented with polymyxin 50U/ml, trimethopim 20mg/l and 
amphotericin B 10mg/l. 
 
The protocol for animal handling was previously approved by University of Zaragoza 
Animal Ethics Committee. 
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Results and Discussion 
Generation of M. tuberculosis knock out mutants 
We have used the method described by Parish et al. (73) to generate three knock-out 
mutants, H37Rv KOTAP, H37Rv KOSTP and H37Rv KOP55, with Rv1258c, Rv2333c and 
Rv1410c genes deleted respectively. 
 
The correspondent suicide plasmid (Table 8) was electroporated in M. tuberculosis H37Rv 
competent cells, and the colonies grown on 7H10/ADC/Hyg/X-Gal that presented lactose 
positive (blue) phenotype, selected as potential SXO candidates. These colonies were 
grown in liquid medium, and subsequently verified by PCR (Table 9).  
 
 
 
 
 
 
 
 
The second event of recombination, which will yield the knock-out mutant, was induced by 
inoculating the SXO strains on 7H10/ADC/Hyg/suc plates. After 4 weeks, the colonies with 
Hyg resistant and lactose negative (white) phenotype were inoculated in liquid medium, as 
they were candidates for DXO mutants. Most of the colonies were lactose positive; they 
were spontaneous mutants to sucrose. Several PCRs were performed to confirm the DXO 
candidates (Table 9). The whole process of knock-out generation took about 6 months. 
 
 
 
 
 
 
 
 
 
 
 
Suicide plasmid Targeted gene Knock-out strain 
pVZ17 Rv1258c H37Rv KOTAP 
pILI9 Rv2333c H37Rv KOSTP 
pILI12 Rv1410c H37Rv KOP55 
Table 8. Suicide plasmids used to generate H37Rv efflux 
pumps knock-out mutants. 
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Rv1258c Size of PCR product (Kb) 
PCR Wild-type SXO DXO 
ctap5 vs Hyg-out --- 0.5 0.5 
Hyg-out vs ctap6 --- 0.5 0.5 
ctap5 vs ctap6  0.7 + 3 3 
Km903-A vs Km903-B --- 1.5 --- 
Rv2333c Size of PCR product (Kb) 
PCR Wild-type SXO DXO 
2333B vs Hyg-out --- 1 1 
Hyg-out vs 2333-med --- 0.4 0.4 
2333B vs 2333-med  1.1 + 3  
Km903-A vs Km903-B --- 1.5 --- 
Rv1410c Size of PCR product (Kb) 
PCR Wild-type SXO DXO 
vec19-up vs Hyg-out --- 0.6 0.6 
Hyg-out vs P55-trans-in --- 0.6 0.6 
vec19-up vs P55-trans-in 0.9 0.9 + 3.2 3.2 
Km903-A vs Km903-B --- 1.5 --- 
 
Confirmation of knock-out mutants by Southern Blot  
Finally, Southern Blot was the definitive test to validate the knock-out mutants (Fig 15-
17). For this, genomic DNA was digested with a restriction enzyme that has little number 
of recognition sites in the genome, generating fragments of different sizes. For each 
knock-out strain, we chose a restriction enzyme that yielded each efflux pump gene in a 
separate fragment. A specific probe was then hybridazed, revealing the fragments that 
contained the efflux pump genes, either wild-type or disrupted by the Ω-Hyg cassette. 
Both the wild-type and the DXO mutant had only one band each, corresponding to the wild 
type and the disrupted gene, respectively. The SXO presented always two bands, one 
containig the wild type and the other containing the disrupted gene; in addition, 
depending on how the suicide plasmid recombinated, two different SXO strains could 
appear. 
 
Table 9. PCRs for confirming SXO and DXO mutants, for the efflux pump genes Rv1258c, Rv2333c and 
Rv1410c.  
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Fig. 16. Southern Blot of Rv2333c (stp) SXO and DXO strains.  
Fig 15. Southern Blot of Rv1258c (tap) SXO and DXO strains. pPAZ11 digested with PstI was used as 
control of hybridization.  
 69 
 
Generation of complementation and overexpression strains 
With the aim of constructing these strains, two kind of plasmids were obtained for each 
efflux pump gene: 
• Replicative plasmids, containing an efflux pump gene under control of its own 
promoter. Plasmids pPAZ11, pSAN17 and pCVZ1 were electroporated in H37Rv, in order 
to generate overexpression strains. All the transformant strains were verified by PCR 
(Table 10).  
 
• Integrative plasmids, with an efflux pump gene under control of its own promoter. 
Plasmids pCRS4, pCRS2 and pCRS3 were electroporated in their respective knock-out 
mutant to obtain the complemented strains. All the transformant strains were verified 
by PCR (Table 11).  
Overexpression strains 
Strain Description 
PCR verification 
Oligonucleotides Size of PCR product (Kb) 
H37Rv pPAZ11 
Overexpression strain 
for Rv1258c (Tap) 
RP-180 vs tap-out1 0,9 
TN5-A vs TN5-B 0,8 
H37Rv pSAN17 
Overexpression strain 
for Rv2333c (Stp) 
RP-180 vs spt-out1 0,8 
TN5-A vs TN5-B 0,8 
H37Rv pCVZ1 
Overexpression strain 
for Rv1410c (P55) 
TN5-A vs TN5-B 0,8 
 
Fig. 17. Southern Blot of Rv1410c (P55) SXO and DXO strains.  
Table 10. PCRs for verification of efflux pump overexpression strains. 
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In summary, for each efflux pump (Rv1258c, Rv2333c and Rv1410c) four H37Rv derivative 
strains have been generated: i) SXO mutant, ii) DXO mutant, iii) the complemented knock-
out strain, and iii) the overexpression strain. All these strains were inoculated in 
7H10/ADC/X-Gal with several combinations of Hyg and Km, as a microbiological test, 
following the scheme shown in Fig. 18.  
 
 
 
 
 
 
Complemented strains 
Strain Description 
PCR verification 
Oligonucleotides Size of PCR product (Kb) 
H37Rv KOTAPc H37Rv KOTAP with pCRS4 pMV361A vs tap-out 0,9 
H37Rv KOSTPc H37Rv KOSTP with pCRS2 pMV361B vs stp-out 1 
H37Rv KOP55c H37Rv KOP55 with pCRS3 pMV361B vs p55-out 1 
Table 11. PCRs for verification of complemented knock-out mutants. 
 
Fig. 18. Microbiological test of the efflux pumps mutant strains. A. Points of inoculation of each strain; 
phenotype is indicated. B. Result of the test, strains grew or not according to their phenotype. 
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Phenotypical characterization of M. tuberculosis efflux pumps mutants 
The generated strains were Neutral Red positive  
Neutral red stain is a fast screening method for testing integrity of the mycobacterial cell 
envelope, because neutral red phenotype seems to be consequence of the absence of more 
than one type of methyl-branched fatty acids (26). Two strains were used as controls (Fig 
19): H37Rv, a virulent strain, as positive control; and MTBVAC, an attenuated strain, as 
negative control. MTBVAC, which has double unmarked phoP and fadD26 deletions, is not 
able to fix neutral red because the fadD26 gene is required for PDIM biosynthesis (91). 
 
Since the generated strains were going to be tested in infection assays, we needed to 
confirm that they hadn’t lost any important lipid for virulence. For this reason, the strains 
with a positive neutral red stain were selected to carry on with the experiments. 
Nontheless, further lipid analysis apart from neutra red stain should be performed to 
assure the integrity of the cell envelope. 
 
 
 
 
 
All the strains had the same lipid profile 
 
By thin layer chromatography, a qualitative lipid analysis, we could answer two important 
questions: i) if the knock-out strains had lost any free-lipid of the cell wall as a 
consequence of the deletion of the efflux pump and, ii) if the strains kept the integrity of 
the cell envelope, which is important for virulence. 
 
First, we extracted free lipids and mycolic acids from the cell envelope of the wild type 
H37Rv strain and its derivatives (Table 12), as well as GC1237 Beijing strain.  
 
 
MTBVAC 
Neutral red 
 positive 
Neutral red 
 negative 
H37Rv 
Fig.19. Neutral red stain of H37Rv (positive 
control) and MTBVAC (negative control) 
strains. 
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Gene Knock-out strains Complemented strains Overexpression strains 
Rv1258c H37Rv KOTAP H37Rv KOTAPc H37Rv pPAZ11 
Rv2333c H37Rv KOSTP H37Rv KOSTPc H37Rv pSAN17 
Rv1410c H37Rv KOP55 H37Rv KOP55c H37Rv pCVZ1 
 
 
Several TLC were performed, each one separating and revealing a group of lipids 
depending of their molecular polarity. All the H37Rv strains showed the same lipid profile, 
so we can conclude that the deletion of Rv1258c, Rv2333c or Rv1410c has no effect on the 
composition of the outer lipid layer of the cell envelope. However, it should be noted that 
this is a general qualitative analysis, so there could be differences only detected with 
more specific techniques. 
 
H37Rv is not producing a functional Pks3 
Pks3 is a polyketide synthase involved in the synthesis of mycolipanolic and mycolipenic 
acids, the trimethyl branched fatty acids present in the polyacyltrehalose of M. 
tuberculosis (10). In the TLC analysis, we observed that H37Rv wild type strain and its 
derivatives didn’t seem to have polyacyltrehaloses, while the Beijing strain GC1237 did. It 
has been reported that H37Rv Pasteur, the strain sequenced by Cole et al.(27), has a C->A 
mutation at position 1467 of the pks3 gene, resulting in a stop codon, whereas other 
strains such us CDC1551 and ATCC 2729 have a tyrosine codon (32). In order to find if the 
H37Rv strain used in our work was not producing a functional Pks3 due to this mutation, 
this region of both H37Rv and GC1237 was sequenced with oligonucleotides pks3-Fw and 
pks3-Rv. Consistenly with the TLC results, we found that H37Rv did have this mutation, 
and GC1237 didn’t. 
 
H37Rv and the knock out mutants have similar growth rates in liquid medium  
The deletion of an efflux pump can affect the fitness of bacteria. With the aim of testing 
the growth rate of the efflux pumps knock out mutants, OD600nm of H37Rv wild type, H37Rv 
KOTAP, H37Rv KOSTP and H37Rv KOP55 were measured for a month. When the cultures 
reached OD600nm~0.5, they were used to start another growth rate experiment. A total of 
three consecutive experiments were done, and this was performed in duplicate. 
Table 12. Strains used for lipid extraction and TLC analysis. 
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As it is observed in Fig. 20, no significant differences were noted between the wild type 
and the knock-out strains. However, a possible difference could be masked by the 
nutrient-rich media; if these efflux pumps are transporting any molecule important for the 
fitness of bacteria, maybe it can only be visualized in a minimum medium. 
 
The P55 knock-out mutant and overexpressing strains have limited growth ability 
on solid media 
Both knock-out and overexpression strains formed smaller colonies than the wild-type after 
two weeks of incubation. However, the colony of  overexpression strain was rougher than 
the one of knock out mutant.  
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Fig. 20. Growth curves of H37Rv, H37Rv KOTAP, H37Rv KOSTP and H37Rv KOP55. 
KO P55 H37Rv H37Rv  H37Rv 
pCVZ1 
Fig 21. Comparison between morphologies of 
wild type (H37Rv) and P55 knock-out (KO 
P55) colonies.  
Fig 22. Comparison between morphologies of 
wild type (H37Rv) and P55 overexpression 
(pCVZ1) colonies.  
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Deletion of P55 efflux pump results in a flat colony, and the rough texture is restored in 
the complemented strain.  
 
 
Susceptibility assays  
Minimum Inhibitory Concentrations were calculated by the resazurin method. Results of 
susceptibility assays are showed in Tables 13-15. Differences in susceptibility are shaded.  
 
Increased susceptibility to spectinomycin (16-fold), gentamicin (2-fold) and streptomycin 
(2-fold) was found for Rv1258c knockout mutant. Deletion of Rv1410c caused a decrease in 
MICs of vancomycin and rifampicin (8-fold). Accordingly, the complemented knockout 
mutants showed wild type susceptibility levels. Rv2333c knockout mutant showed 
increased susceptibility to vancomycin, but wild type susceptibility levels are not reached 
in the complemented strain. 
 
Rv1258c	  
Compound	  
MIC	  (mg/l)	  
H37Rv	   KOTAP	   KOTAPc	  
Spectinomycin	   128-­‐64	   8-­‐4	   64-­‐32	  
Streptomycin	   0,4	   0,2	   0,4	  
Ethambutol	   2	   2	   2	  
Gentamicin	   4	   2	   4	  
Isoniazid	   0,4	   0,4	   0,4	  
Tetracyclin	   4	   4	   4	  
Triclosan	   32	   32	   32	  
Chloramphenicol	   4-­‐2	   4-­‐2	   4-­‐2	  
Acriflavine	   2	   2	   2	  
  
 
 
 
 
 
 
KOP55 KOP55c 
Fig 23  Morphology of  P55 knock-out mutant (KOP55) and  
complemented strain (KOP55c) colonies after two months of  
growth. 
Table 13. MICs of Rv1258c knock out and complemented strains. 
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Rv1410c	  
Compound	   MIC	  (mg/l)	  
H37Rv	   KOP55	   KOP55c	  
Isoniazid	   0,4	   0,4	   0,4	  
Gentamicin	   4	   4	   4	  
Triclosan	   32	   32	   32	  
Vancomycin	   4-­‐2	   0,5-­‐0,25	   2-­‐1	  
Rifampicin	   0,0128-­‐0,0064	   0,0016	   0,0064	  
Tetracyclin	   4	   4	   4	  
Chloramphenicol	   4-­‐2	   4-­‐2	   4-­‐2	  
Acriflavine	   4	   2	   2	  
 
 
 
 
Rv2333c	  
Compound	   MIC	  (mg/l)	  
H37Rv	   KOSTP	   KOSTPc	  
Rifampicin	   0,0064	   0,0064-­‐0,0032	   0,064-­‐0,0032	  
Chloramphenicol	   4	   4	   4	  
Triclosan	   32	   32	   32	  
vancomycin	   4-­‐2	   1	   1	  
Isoniazid	   0,4	   0,4	   0,4	  
 
 
 
 
 
Infection assays 
Intracellular replication in J774 
Intracellular replication of knock-out, complemented and the wild type strains was tested 
in J774 mouse macrophage-like cells. The multiplicity of infection (MOI) was 0.5-1 bacteria 
per macrophage. At 4 h and 1, 3, 5 and 7 days post-infection, intracellular bacteria were 
counted. (Fig 23, 24, 25).  
 
Infection assays in mouse macrophages showed that Rv1258c, Rv2333c and Rv1410c efflux 
pumps could be implicated in virulence, as they have less intracellular replication than the 
wild type. 
Table 14. MICs of Rv1410c knock out and complemented strains. 
 
Table 15. MICs of Rv1410c knock out and complemented strains 
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Fig. 23. Replication of efflux pump mutants referred to 4h post-infection in J774 mouse macrophage-
like cells. N: number of viable intracellular bacteria on the respective day post- infection. N0: number of 
viable intracellular bacteria on 4h post- infection. A. Rv1258c mutants. B. Rv2333c mutants. C. Rv1410c 
mutants. 
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Apoptosis induction in cells J774 
 
Level of apoptosis induced by wild-type and knock-out mutants was determined in J774 
mouse macrophage cells. J774 cells were infected with H37Rv, KOTAP and KOP55 and 
marked with annexin-V and 7-AAD. By analysis of J774 infected cells by flow citometry, the 
proportion of cells in an apoptotic state can be found. The apoptotic cells show annexin 
fluorescence, but don’t show 7-AAD fluorescence. 
 
No differences in the proportion of apoptotic cells infected with wild-type and knock-out 
mutants were found (Fig 24). 
 
 
 
 
 
 
P55 shows an attenuated phenotype in mouse model infection 
 
The wild type strain and the three knock-out mutants were tested in immunocompetent 
mice C57BL/6. Infection was carried out inoculating 150-300 CFUs via intratracheal 
injection. After three weeks of infection, mice were sacrified and viable counts were 
performed on serial dilutions of the homogenized lungs. Table x shows the Replication of 
efflux pumps mutants in mouse lung.  
Fig.24. Analysis of annexin-V and 7-AAD fluorescence of J774 cells by flow citometry.  
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Among the three knock out mutants, the only one that showed an attenuated phenotype in 
immunocompetent mice was KOP55. However, these experiments are going to be done in 
immunodeficient mice, in which we can see more clearly if there is a contribution to 
virulence. 
 
  
Fig. 25. Replication of efflux pumps mutants in mouse lung. Average Log CFU of 
the inoculum suspension and at week 3 post-infection.  
 
0	  1	  
2	  3	  
4	  5	  
6	  7	  
0	   0,5	   1	   1,5	   2	   2,5	   3	   3,5	  
Lo
g	  
CF
U
	  
t	  (weeks)	  
H37Rv	  KOTAP	  KOSTP	  KOP55	  
 79 
Conclusions 
 
• The efflux pump Rv1258c (Tap) of M. tuberculosis is implicated in intrinsic resistance 
to streptomycin, gentamicin and spectinomycin. The knock out mutant of tap didn’t 
show a difference in susceptibility to tetraclycine compared to the wild type H37Rv 
strain, as it did with M. bovis BCG model. Infection assays in mouse macrophage cell 
model revealed that Tap could have a role in virulence. However, the knock-out 
mutant of Rv1258c had the same phenotype as H37Rv in infection assays in 
immunocompetent mouse model.  
 
• Rv1410c (P55) efflux pump of M. tuberculosis is contributing to intrinsic resistance to 
rifampicin, one of the two main antibiotics in antituberculous treatment, and 
vancomycin. H37Rv knock-out mutant of Rv1410c has altered growth in solid media: it 
grew more slowly than the wild-type and showed a flatter and smoother morphology of 
colony. Mouse macrophage cell infection assays and in vivo infection 
(immunocompetente mice) showed that P55 has a role in virulence of M. tuberculosis. 
 
• H37Rv knock-out mutant of Rv2333c (Stp) didn’t show increased susceptibility to 
tetracycline and spectinomycin, as it did M. bovis BCG Rv2333c knock-out mutant. 
Infection assays in mouse macrophage cell model revealed that Stp could have a role 
in virulence. However, infection assays of immunocompetent mice showed no 
difference between the replication in lungs of the knock-out mutant of Rv2333c and 
that of H37Rv wild-type strain. 
 
• Rv1258c, Rv2333c and Rv1410c don’t seem to be implicated in apoptosis induction of 
mouse macrophage cells. 
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Chapter 2 
 
Analysis of mutations conferring 
streptomycin resistance of M. tuberculosis 
reveals a SNP in Rv1258c gene 
 
 
 
 
 
 
This part of the study is presented as a manuscript, which was submitted and is 
currently under review, with positive feedback from the referees, and high 
possibility of being published. 
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ABSTRACT 
 
Mycobacterium tuberculosis pandemic is a major health problem worldwide, further 
complicated by increasing incidence of drug resistant isolates and the existence of 
highly transmissible strains, such as those of the Beijing family. We have analysed 
streptomycin (STR) resistant M. tuberculosis clinical isolates, looking for mutations in 
rpsL, rrs and gidB genes. In addition, we also sequenced Rv1258c gene encoding Tap, 
an efflux pump transporting STR. Mutations affecting codons 43 and 88 of rpsL gene 
were found in 44,4% of the strains, and 16,7% of the strains carried mutations in rrs 
gene, probably contributing to STR resistance. Many strains presented mutations in 
gidB gene but their implication in STR resistance remains unclear. Interestingly, we 
found a cytosine nucleotide insertion between positions 580 and 581 of the Rv1258c 
gene (denominated Tap580) in all Beijing isolates included in this study, suggesting it 
could be a novel polymorphism specific of the Beijing family of M. tuberculosis. We 
have developed a simple and fast PCR-RFLP method for detecting Tap580 insertion, 
that was applied to screen a collection of 220 DNA samples obtained from cultures of 
M. tuberculosis isolates and seven respiratory specimens. In all cases, we were able 
to identify correctly all the Beijing and non-Beijing representatives. Tap580 is a novel 
polymorphism specific of the highly transmissible Beijing family, which allows a fast 
detection of these strains even at very early stages of infection. 
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INTRODUCTION 
 
Mycobacterium tuberculosis still constitutes the cause of millions of incident cases of 
tuberculosis and deaths worldwide (28), many of them among HIV-positive patients. 
This global pandemic is further complicated by the increased incidence of drug 
resistant strains (28), which generally have accumulated mutations in genes encoding 
drug target or drug activating enzymes. Nevertheless, there are resistant strains in 
which no mutations linked to drug resistance have been identified, hence suggesting 
yet unidentified drug target proteins or novel mechanisms of drug resistance. A 
paradigm of this is the case of STR, a first line antituberculosis drug of increasing use 
in our days due to the raising incidence of multi and extensively drug resistant strains 
(MDR and XDR respectively). Mutations in genes rpsL, rrs and gidB (encoding S12 
ribosomal protein, 16S rRNA and ribosome methyltransferase, respectively) have 
been found in ca. 70% of M. tuberculosis isolates resistant to STR; in the rest of STR 
resistant M. tuberculosis strains, the cause of drug resistance remains unknown. 
Molecular techniques have allowed the differentiation of several lineages and 
families among M. tuberculosis strains, which differ not only in global geographical 
distribution but also in terms of transmissibility, drug resistance, treatment outcome 
and other factors. The Beijing family of M. tuberculosis isolates are characterised by 
their increased ability to spread and cause disease and their increased association 
with drug resistance (10). Because of this, many methods have been developed 
aimed at identifying and differentiating M. tuberculosis Beijing isolates (4), (16), 
(20), (14). There are several methods for identifying Beijing isolates, including 
spoligotyping, RFLP using IS6110 as a probe, or the presence of a copy of IS6110 in 
the dnaA region (12); others are based on the detection of specific genomic deletions 
such as RD105 or an intact pks15/1 gene (24). Recently, the detection of a single-
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nucleotide polymorphism (SNP) in the Rv2629 gene by using real-time PCR followed 
by high-resolution melting has also been described (4). 
In this work, we present the analysis of target mutations in clinical isolates of M. 
tuberculosis resistant to STR. In addition, we investigated the nucleotide sequence of 
Rv1258c gene encoding the drug efflux pump Tap from M. tuberculosis, which 
transports STR and other antibiotics, as we have previously described (2), (8), (19), 
as a potential STR resistance determinant. We identified a nucleotide insertion in the 
coding sequence of the Rv1258c gene, which does not seem to be associated with 
resistance to this drug. Interestingly, this insertion is exclusive of the Beijing family 
of M. tuberculosis isolates and has led to the development of a method for screening 
M. tuberculosis strains (either purified DNA or directly on respiratory samples) and 
reliably identifying those belonging to the Beijing family of strains. 
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MATERIALS & METHODS 
 
M. tuberculosis DNA samples 
First, DNA samples of 18 M. tuberculosis clinical isolates resistant to STR and some 
additional drugs (including several MDR isolates), of the Universidad de Zaragoza 
culture collection, along with the control strain H37Rv (fully drug susceptible) were 
used as template to amplify and sequence the target genes (rpsL, rrs, gidB and 
Rv1258c). This group included 4 strains that had a spoligotyping consistent with being 
of the Beijing family. 
Next, we analysed 220 DNA samples from M. tuberculosis complex clinical isolates 
collected from Hospitals in Huesca, Zaragoza, Madrid and Barcelona (Spain). These 
isolates included samples from a Spanish national survey on MDR M. tuberculosis 
done between 1998 and 2009. This set included 49 DNA samples having a 
spoligotyping consistent with those of the Beijing family, 158 were representative of 
other M. tuberculosis distinct lineages (LAM, T, X, S, Haarlem, CAS, EAI and others, 
including 5 isolates of the MTZ strain, a highly transmissible M. tuberculosis strain 
that has caused major outbreaks in Zaragoza (13) and 13 were M. africanum (Table 
3). Overall, we got isolates representative of most of M. tuberculosis genetic 
lineages described (9). In these samples, we investigated the presence of the novel 
nucleotide insertion in Rv1258c gene described in this work. We selected 30 DNA 
samples (18 from Hospital Germans Trías i Pujol, Badalona and 12 from Hospital 
Gregorio Marañón, Madrid), those originated from STR resistant isolates (five of them 
belonged to the Beijing family), and the Rv1258c gene was completely sequenced in 
order to verify the presence of the nucleotide insertion in Rv1258c gene described in 
this work, and to identify other potential mutations. 
 
PCR amplification and sequencing 
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The primers used for amplifying and sequencing genes related with STR resistance, 
the annealing temperature used in the PCR reaction, and the size of the product are 
listed in Table 1. PCR reactions were performed in a final volume of 50 µl using 200 
µM of each dNTP, 5 µl of Buffer (10x PCR Buffer, Applied Biosystems), 1.25 U of Taq 
Gold polymerase (Applied Biosystems), 0.25 µM of each primer, 5 µl of dimethyl 
sulphoxide and 2 µl of DNA (20-100 ng/µl). Amplifications consisted of an initial step 
at 94 ºC for 10 min, followed by 40 cycles of 1 minute at 94 ºC, annealing for 2 
minutes (see Table 1) and 2 minutes at 72 ºC, with a final extension step of 10 min at 
72 ºC. All genes were amplified in one single product, except Rv1258c gene that was 
amplified in two overlapping products, one containing the promoter and the first half 
of the coding sequence, and the second containing the rest of the gene. 
PCR products were purified using ExoSAP-IT (Affymetrix) and sequenced using the 
same primers used for the amplification. Sequences were then analysed by 
comparison with that of the reference H37Rv strain (Cole et al. (6); TubercuList, 
http://tuberculist.epfl.ch/). 
Screening of nucleotide insertion in Rv1258c gene 
Firstly, an internal fragment of Rv1258c gene containing the location of the cytosine 
nucleotide insertion between positions 580 and 581 of the coding sequence of the 
Rv1258c gene (denominated Tap580) was amplified using primers ctap9 and ctap10 
(Table 1). DNA samples were processed 9 minutes at 94 ºC, followed by 35 cycles of 
30 seconds at 94 ºC, annealing for 30 seconds at 65 ºC, extension at 72 ºC for 1.5 
minutes, and final extension at 72 ºC for 10 minutes. We obtained a product of 1052 
bp, which was digested for 1 hour at 37 ºC with XhoI restriction enzyme, followed by 
electrophoresis in 0.8% agarose gel in TBE buffer. As a control of endonuclease 
digestion, PCR products were digested for 1 hour at 37 ºC with PvuII restriction 
enzyme, which produces two fragments of 610 and 442 nucleotides for both Beijing 
and non-Beijing isolates. 
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Bioinformatic analysis 
Databases of bacterial genomes were analysed using the program Blast at NCBI 
(National Center for Biotechnology Information, http://blast.ncbi.nlm.nih.gov/) in 
search for Tap580 insertion in Rv1258c gene among sequenced genomes of the M. 
tuberculosis complex. Last access was on July 26th 2012. 
 
Screening of Tap580 insertion in Rv1258c gene directly in respiratory samples 
Seven respiratory samples from patients diagnosed with tuberculosis were obtained 
from Servicio de Microbiología (Hospital Universitario Lozano Blesa, Zaragoza, Spain). 
All samples were smear positive (their bacillary load ranged from 2 to >100 
bacilli/field) and culture positive. Samples were decontaminated by N-acetyl-L-
cysteine/NaOH, and a fraction was incubated 20 minutes at 80 ºC for killing the live 
bacilli and extracting DNA using the kit GenoLyse® (Hain Lifescience).  
 
 
 
93 
RESULTS & DISCUSSION 
 
Mutations in rpsL, rrs and gidB genes 
In order to find the mutations responsible for STR resistance in 18 M. tuberculosis 
clinical strains, we sequenced first the genes rpsL, rrs and gidB that are known to 
carry mutations related with resistance to STR and compared them with the 
sequence of STR-susceptible H37Rv laboratory strain available in the TubercuList 
database (http://tuberculist.epfl.ch/). All strains analysed in our study, including 
the reference H37Rv strain, had mutations A363G in rpsL and C299T in gidB, which 
have been reported as sequencing errors in the sequence of H37Rv included in both 
TubercuList database and GenBank entry AL123456.2 Ioerger, et al. (11), (31). 
Significant mutations found in the strains analysed in our study are summarised in 
Table 2. 
Eight of the strains tested (44.4%) carried mutations in rpsL gene, being the mutation 
A128G found in six of them. The four Beijing strains included in this group carried 
this mutation, which is the most frequent mutation found in STR resistant M. 
tuberculosis Beijing strains (17, 23). Two other strains (11.1%) had the mutation 
A263G. 
Four strains (22.2%) harboured mutations in the rrs gene. Three strains carried 
mutations C340T, A324G and A736G, respectively; to our knowledge this is the first 
report on mutations in this region. The latter strain also carried mutation C462T 
according to Tuberculist numbering, mutation that has been already documented as 
C461T (5). Finally, one strain carried mutation C492T close to the 530 loop of the 
secondary structure of M. tuberculosis 16S rRNA; this strain is further discussed 
below. 
The role of GidB protein in conferring high-level STR resistance in M. tuberculosis has 
been fully characterised (29), although the contribution of certain point mutations to 
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STR resistance is still controversial; it has been speculated that some mutations in 
gidB gene would promote the acquisitions of mutations in either rpsL or rrs (18). A 
large number of mutations (including many silent mutations) were found in the gidB 
gene, in fact, only four strains had a gidB gene identical to that of H37Rv. Many 
missense mutations have been described in STR susceptible strains, such as the 
mutation T47G (the most frequent mutation found in our study) that has been 
reported as specific of the Latin-American-Mediterranean (LAM) family strains (21)); 
in fact, the 6 strains carrying this mutation belonged to the LAM family of strains 
(data not shown). The four Beijing strains carried two mutations: A276C (E92D) that 
has been described as a SNP specific of this family (21), and A615G; both mutations 
can be found in STR susceptible strains (29). In the Beijing strains, these gidB 
mutations occur simultaneously to mutation A128G in rpsL gene as mentioned above. 
Among the non-Beijing strains, gidB C413T mutation has been found both in STR 
resistant and susceptible M. tuberculosis isolates (18, 26, 29). In one STR resistant 
isolate, we found mutation G248C, likely indicating that it could lead to resistance to 
this drug; however, other mutations in this position (G248T) have been found in STR 
susceptible strains (18). Finally, the only gidB mutation potentially related with 
resistance to STR could be the missense mutation G490C, since this one was detected 
in a strain lacking mutations in rpsL and rrs genes. 
We found mutations in all three genes in one strain; these were rpsL A128G, rrs 
C492T and gidB T47G. In this strain STR resistance will be due to the mutation rpsL 
A128G, since the two other mutations have been found in both STR resistant and 
susceptible isolates. Mutation rrs C492T, also reported elsewhere as C491T, has been 
associated to LAM3 genetic lineage of M. tuberculosis (25, 27). This very same 
genetic lineage of M. tuberculosis also carries mutation T47G as mentioned above 
(21). 
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Finally, one of the STR resistant strains lacked mutations in any of these three genes. 
In three others, only mutations in gidB were found, although these were either silent 
or have been described also in STR susceptible strains, hence making unlikely that 
they may have a major contribution to resistance to this drug. This confirms that 
other mechanisms must contribute to STR resistance in M. tuberculosis. 
 
Mutations in Rv1258c gene 
We hypothesize that since STR is a substrate of Rv1258c efflux pump (19), mutations 
affecting expression levels of Rv1258c gene or changing kinetic properties of the 
efflux pump could contribute to STR resistance. To further investigate this, we 
amplified and sequenced the Rv1258c gene in the 18 samples of M. tuberculosis STR 
resistant clinical strains in which we had sequenced rpsL, rrs and gidB genes. We 
found two different mutations in Rv1258c gene. One strain has a deletion of the 
adenine nucleotide in position 13 (Table 2) producing a frameshift; as a result, a TGA 
stop codon will end translation of a peptide of only 10 amino acids. Four strains have 
an insertion of a cytosine nucleotide between positions 580 and 581 (Table 2); this 
insertion, which in this work we will refer to as Tap580, causes a frame-shift mutation 
from codon 194 onwards, resulting in a shorter protein (231 amino acids). This 
protein probably would not constitute a functional membrane transporter, since it 
contains only 6 transmembrane segments (TMS) in comparison with the 12 TMS of the 
full-length protein (419 amino acids) (Figure 1). Bacterial drug efflux pumps of the 
Major Facilitator Superfamily have 12 or 14 TMS, which are required for transport 
activity. 
These five strains carrying mutations in Rv1258c gene also carried mutations A263G 
(K88R) or A128G (K43R) in rpsL gene, which probably will be responsible for the high-
level STR resistance making difficult to analyse the contribution of Rv1258c 
mutations in resistance to this drug. 
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Remarkably, we noticed that the four strains carrying Tap580 insertion had been typed 
as belonging to the Beijing lineage by either RFLP and/or spoligotyping (data not 
shown). We hypothesized that this could represent a novel polymorphism specific of 
the Beijing family. To test this, we inspected the presence of Tap580 insertion in 
thirteen genomes of M. tuberculosis available in public databases (NCBI, last access 
was on July 26th 2012), including clinical isolates, laboratory strains such as H37Rv 
and H37Ra, and two strains of the Beijing family. Interestingly, only CCDC5079 and 
CCDC5081 that belong to Beijing family (30) had the Tap580 insertion (Table 4), 
further supporting that Tap580 is a specific insertion of the Beijing family isolates. 
Other species of the M. tuberculosis complex, such as four substrains of M. bovis BCG 
and M. bovis AF2122/97 did not show Tap580 polymorphism and had complete identity 
with Rv1258c gene of H37Rv (Table 4). 
 
The Tap580 insertion is present in clinical strains of the Beijing family of isolates 
We further investigated the presence of Tap580 insertion in different subtypes of the 
Beijing family of isolates, and in isolates of other genetic families. 
For this, we first developed a quick and simple method for detecting Tap580 insertion. 
Between positions 577 and 582 of the Rv1258c gene, the sequence CTCGAG is the 
target for XhoI endonuclease; insertion of a cytosine nucleotide in Beijing strains 
results in CTCGCAG that is not recognized by this endonuclease (Figure 2). We 
designed two primers for amplifying a fragment of 1052 bp of the Rv1258c gene, from 
nucleotides 165 to 1216, which includes the position of the Tap580 insertion. Digestion 
of PCR products with XhoI endonuclease resulted in two DNA fragments of 413 and 
639 bp in the case of non-Beijing strains, whereas PCR products from Beijing strains 
remained unaffected (Figure 2). 
We proceeded then to screen a collection of 220 clinical isolates of M. tuberculosis 
complex, which included 49 isolates having spoligotyping consistent with that of the 
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Beijing family. DNA samples were given random numbers and were blind tested using 
our PCR-RFLP method described above. We found that Tap580 insertion was present in 
all Beijing strains and absent in all strains belonging to other lineages of M. 
tuberculosis; Tap580 insertion was also absent from M. africanum isolates (Table 3). 
We included two controls in our assays. First, in each experiment we included 
samples of DNA from the laboratory strain M. tuberculosis H37Rv (which does not 
belong to the Beijing family of isolates), and from the M. tuberculosis GC1237 strain 
(a Beijing isolate recently characterised (3)). The PCR product from M. tuberculosis 
H37Rv was cut by XhoI, whereas that of M. tuberculosis GC1237 strain was not cut, 
confirming that all steps in the identification process were carried out satisfactorily. 
Second, all PCR products were digested with PvuII restriction enzyme, which cuts the 
amplification products of Rv1258c gene obtained from both Beijing and non-Beijing 
samples, demonstrating that the amplification step has been specific of Rv1258c 
gene and ruling out the possibility of unspecific amplifications. 
Finally, out of the 220 samples, we sequenced Rv1258c gene in the 30 M. 
tuberculosis STR resistant clinical isolates from Hospital Gregorio Marañón (Madrid, 
Spain) and Hospital Germans Trias i Pujol (Badalona, Spain). We found consistently 
that Tap580 insertion was present in the 5 Beijing and absent in all the non-Beijing 
strains, hence validating the method for screening Tap580 insertion developed in this 
work. In addition, we found a deletion of 4 nucleotides spanning positions 835 and 
838 of the Rv1258c gene in one of the Beijing samples, which is located downstream 
of the in-frame stop codon in position 694-696 produced by Tap580 insertion. 
 
Detection of the Rv1258c nucleotide insertion in clinical samples 
In order to assess the usefulness of this technique for detecting Beijing strains 
directly in clinical samples, we analysed seven respiratory samples with diverse 
bacillary load and positive for culture of M. tuberculosis. After isolating the DNA 
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from sputum samples, we successfully amplified the 1052 bp PCR product from all 
samples, including those having a low bacillary load, and digested with XhoI 
endonuclease. All seven M. tuberculosis strains present in sputum samples were 
identified as non-Beijing, in agreement with spoligotyping.  
The precise effect of this nucleotide insertion in the physiology of M. tuberculosis 
Beijing isolates remains to be fully elucidated. Recently, the role of Rv1258c efflux 
pump in drug tolerance in M. tuberculosis has been reported (1). Since the identified 
single nucleotide insertion in Rv1258c gene in Beijing isolates results in a truncated, 
and most probably inactive protein, this would suggest that isolates carrying this 
nucleotide insertion could have a disadvantage in terms of drug resistance and drug 
tolerance in comparison with others carrying a fully functional Rv1258c transporter. 
However, since Beijing isolates are frequently associated with a higher propensity to 
acquire drug resistance, it is conceivable that other mutations are actually 
compensating the loss of Rv1258c in this family of M. tuberculosis isolates. Examples 
of compensatory mutations occurring following the acquisition of drug resistance 
associated mutations have been described for M. tuberculosis (7). 
In summary, we have found a new genetic polymorphism of M. tuberculosis Beijing 
strains, which has been used to develop a simple and reliable technique for 
identifying isolates of this family. Given the higher transmissibility rate of this family 
of strains, which in addition are more prone to develop drug resistance, methods for 
rapid identification constitute a very important tool for the control of outbreaks 
caused by isolates of the Beijing family of strains. This technique is fast since it can 
be performed directly on clinical specimens and there is no need for culturing 
strains, making it an ideal method for being implemented in those settings where 
routine culture of clinical samples cannot be done. In addition, this technique is easy 
to carry out and does not require sophisticated equipment since only a thermocycler 
and DNA electrophoresis system are needed. In addition, samples can be processed 
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individually or in groups of any size, and this can easily accommodate to the 
workflow of a clinical laboratory, without the need for processing samples in groups 
of a fixed number. All this, along with the specificity for both detection of M. 
tuberculosis and identification of Beijing family of strains, make it ideal for 
implementation in clinical laboratories, specially in those settings with a high 
incidence of tuberculosis infections caused by this family of strains.  
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Figure 1. Hydrophobicity profile and transmembrane prediction of the Rv1258c 
proteins of M. tuberculosis H37Rv (A) and Beijing isolates (B), using the Hidden 
Markov Model (TMHMM Server v. 2.0, Center for Biological Sequence Analysis, 
Technical University of Denmark, http://www.cbs.dtu.dk/services/TMHMM/). 
 
Figure 2. Screening of the insertion Tap580 of Beijing strains. A. DNA gel 
electrophoresis showing PCR product with primers ctap9 and ctap10 digested with 
XhoI. M. Size marker, lambda DNA digested with PstI. 1. GC1237 (Beijing). 2. H37Rv 
(non Beijing). B. Sequence of the region of Rv1258c gene in a Beijing strain (1) and 
H37Rv strain (2) (GenBank AL123456.2). 
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TABLE 1. Primers used for amplification in this study. 
Target PCR product (bp) Tac (ºC) Primer Sequence 5’->3’ Reference 
For amplifying and sequencing 
rpsL 501 52 
S13 GGCCGACAAACAGAACGT (15) 
S16 GTTCACCAACTGGGTGAC (15) 
rrs 1037 58 
264 TGCACACAGGCCACAAGGGA (22) 
285 GAGAGTTTGATCCTGGCTCAG (22) 
gidB 977 56 
gidB3 GAACGGAAGATCGTCCAC This work 
gidB4 CGATAGTTGAAGCCTGGC This work 
Rv1258ca 830 58 
ctap1 CAATGTGGATTACCGCGAC This work 
ctap2 GTCTTGCCGGTAGCCGTC This work 
Rv1258cb 902 58 
ctap3 CGCAGGTTCCAGACGAAG This work 
ctap4 GATCAGCGCGTTGAGTTC This work 
For detection of nucleotide insertion 
Rv1258c 1052 65 
ctap9 GGCCGACAAACAGAACGT This work 
ctap10 GTTCACCAACTGGGTGAC This work 
a 3’ region of Rv1258c gene. 
b Promoter and 5’ region of Rv1258c gene. 
c Ta= annealing temperature 
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TABLE 2. Mutations found in rpsL, rrs, gidB and Rv1258c genes in strains of the Universidad de Zaragoza culture collection. 
 
M. tuberculosis 
SM-resistant 
Mutation found in: 
Strain 
rpsL rrs gidB  Rv1258c 
DNA Protein DNA DNA Protein DNA Protein 
Z-07044   C340T     
Z-07047a A128G K43R  A276Cb E92D InsC 580-581 194 frameshift 
    A615Gb silent   
HMS-1838    C413Tb A138V   
HCU-2879 A263G K88R      
HCU-2934 A128G K43R  T47Gb L16R   
HCU-2830a A128G K43R  A276Cb E92D InsC 580-581 194 frameshift 
    A615Gb silent   
HMS-1695 A128G K43R C492T T47Gb L16R   
HMS-1691 A263G K88R    A13del 5 frameshift 
HMS-1781    G490C G164R   
VEN-4145a A128G K43R  A276Cb E92D InsC 580-581 194 frameshift 
    A615Gb silent   
VEN-1714    T47Gb L16R   
    C409Gb R137G   
 108 
VEN-5292   A324G T47Gb L16R   
    T149C L50P   
VEN-2457    T47Gb L16R   
VEN-1667    T47Gb L16R   
    G248C R83P   
VEN-2543        
VEN-314    C159T silent   
VEN-4237   C462T C159T silent   
   A736G     
VEN-3748a A128G K43R  A276Cb E92D InsC 580-581 194 frameshift 
    A615Gb silent   
a Strains belonging to Beijing family. 
b Mutations found in susceptible strains (18, 26, 29) 
 
  
 
 
109 
TABLE 3. Number of strains belonging to different lineages used in Tap580 screening. 
 
Lineage / species No. of strains 
Beijing 49 
T 27 
LAMa 25 
HAARLEM 18 
U 16 
CASb 12 
EAIc 9 
S 2 
X 1 
Not assigned 48 
M. africanum 13 
TOTAL 220 
a LAM: Latin American and Mediterranean lineage 
b CAS: Central-Asian lineage 
c EAI: East African-Indian lineage 
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TABLE 4. Search for Tap580 insertion by bioinformatics analysis of M. tuberculosis complex 
sequenced genomes. 
 Strains 
Beijing 
lineage 
Tap 580 
Mycobacterium tuberculosis     
   
H37Ra No No 
H37Rv  No No 
CCDC5079  Yes Yes 
CCDC5180  Yes Yes 
CDC1551 No No 
CTRI-2 No No 
F11 No No 
KZN 1435 No No 
KZN 4207 No No 
RGTB327 No No 
RGTB423 No No 
str. Erdman = ATCC 35801 DNA.  No No 
UT205  No No 
   
Mycobacterium bovis     
   
BCG Pasteur 1173P2.   No 
BCG Mexico.   No 
BCG. Moreau RDJ   No 
BCG. Tokyo 172 DNA.   No 
AF2122/97  No 
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Comments 
 
The Beijing family 
 
The M. tuberculosis Beijing genotype family constitutes a homogeneous group of strains 
sharing a closely related IS6110 RFLP patterns containing a high number of bands, identical 
spoligotyping (deletion of spacers 1 to 34 in the Direct Repeat region) (106), an insertion of 
IS6110 between dnaA-dnaN genes (54) and one or two IS6110 copies in a DNA region called 
NTF locus (53, 54) 
 
Different studies have indicated that one-third of global TB cases is caused by Beijing 
family strains assigning this lineage to one of the most successful mycobacterial families in 
terms of morbidity and mortality (12). In some areas, such as Vietnam, Cuba, and Estonia, 
Beijing strains were found to be strongly associated with drug resistance (8, 14, 31, 52). M. 
tuberculosis GC1237, which belongs to the Beijing family, has been responsible for 
different epidemic outbreaks in the Gran Canary Island since 1991, representing the 25% of 
the cases of tuberculosis in the year 2007-2008 (24, 64). GC1237 is the strain used for 
Beijing control in the PCR-RFLP method. 
 
A number of selective advantages have been associated with its success including a lower 
efficacy of BCG for Beijing strains (60, 106) higher virulence (60, 62), ability to induce a 
differential immune response (33, 61), higher transmissibility (12) and enhanced capacity 
to grow in human macrophages and monocytes (57, 112) and an enhanced capacity to 
acquire drug resistance (2, 13, 14) 
  
The PCR-RFLP method described in the manuscript, constitutes a fast, easy and 
inexpensive method of detecting Beijing strains, even at early stages of infection. This tool 
can be helpful to detect this highly virulent and transmissible strains, allowing a better 
control of outbreaks. 
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Chapter 3 
 
Complementation of E. coli efflux pumps knock 
out mutants with MFS and RND transporters of 
M. tuberculosis  
 
 
 
 
 
 
 
 
 
This part of the study was done in the “Infectious Diseases Division”, University Hospital of 
Freiburg, Germany. 
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Introduction 
Efflux pumps from RND family 
Efflux pumps are present both in gram positive and negative bacteria, and they are related 
with multidrug resistance and other bacterial processes such us colonization and 
persistence in the host (78). Major Facilitator Superfamily (MFS) and Resistance-
Nodulation-Cell Division Superfamily (RND) are two of the main membrane transporters in 
bacteria (58).  
AcrAB-TolC, the main RND efflux pump in E. coli 
Escherichia coli has seven RND efflux pumps, from which the most important in multidrug 
resistance is AcrAB-TolC (19). This transporter is constituted by three assembled proteins: 
AcrB (the RND protein, located in the inner membrane), AcrA (a periplasmic fusion protein) 
and TolC (a cannel located in the outer membrane), substrates can be extruded directly to 
the exterior of the bacterium. Multidrug resistance in E. coli is usually asociated with 
AcrAB-TolC overexpression (77). Other important efflux pumps in E. coli are MdfA (MFS) 
and EmrE (SMR), located in the inner membrane and transporting substrates to the 
periplasmic space; thus they need to be coordinated with other efflux pumps, such as 
AcrAB-TolC, to completely export compounds. Ethidium bromide and acriflavine are 
substrates of both MdfA and EmrE so, if one of them is deleted, the other can compensate 
the effect. Consequently, if both are deleted, then the effect is similar to the inactivation 
of acrB gene (97). 
MmpL efflux pumps, the RND proteins of M. tuberculosis. 
Mycobacterium tuberculosis contains 13 RND transporters, named MmpL (Mycobacterial 
Membrane Protein Large), and that have certain homology with AcrB from E. coli. 
Colocalization of mmpL genes with genes of the lipid metabolism induced to think that 
they may be related with lipid transport. That is the case of MmpL7, which transports 
pthiocerol dimycocerosate (PDIM) and MmpL8, whose substrate is a SL-1 precursor, both 
lipids of the mycobacterial cell wall. Part of MmpL proteins are implicated in virulence of 
M. tuberculosis, but no significant contribution to intrinsic resistance has been found (32). 
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Expression of heterologous genes in E. coli 
Previous studies have proved that efflux pumps from heterologous microorganisms can be 
functionally expressed in E. coli: MexB from Pseudomonas aeruginosa was able to partially 
complement AcrB knock-out strain of E. coli (109), and Mmr from M. tuberculosis (a SMR 
protein) was functional when expressed in E. coli (70). 
  
Influence of the codon usage 
There are marked differences in codon usage from one organism to another. Significant 
variation in codon usage patterns among genes in one organism appears to be associated 
with their expression levels. Genes with a high proportion of optimal codons are highly 
expressed, whereas those with rare codons are poorly expressed. Moreover, the presence 
of rare codons can cause ribosome stalling, slow translation, premature translation 
termination and translation errors and therefore inhibit proper protein synthesis and even 
cell growth. To avoid the potential expression problems resulting from rare codons, one 
can either optimize codon usage in the target gene by silent mutations for expression in E. 
coli or expand the intracellular tRNA pool of rare codons by introducing a plasmid which 
encodes these tRNAs. Both strategies have been successfully used to enhance the 
expression of heterologous genes with rare codons in E. coli. However, negative results 
have been reported indicating that factors other than codon usage can affect protein 
expression (43).  
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Objectives 
 
1. To express Rv1258c and Rv1410c (MFS) efflux pumps of M. tuberculosis in E. coli 
wild type, mdfA (MFS) and emrE (SMR) single and double knock out mutants to 
determine susceptibility assays to different substrates, including those already 
confirmed in mycobacteria.  
 
2. To express MmpL7 (RND) efflux pump of M. tuberculosis in E. coli ∆acrB, in order to 
test its ability to reconstitute a functional AcrA-MmpL7-TolC efflux transporter. 
 
3. To perform efflux and accumulation techniques to corroborate potential substrates 
of these transporters. This would provide a new and fast model for studying efflux 
kinetics of mycobacterial efflux pumps using E. coli. 
 
4. To characterize M. tuberculosis mutants deleted in genes encoding MmpL7 and 
MmpL10, by determination of their levels of intrinsic drug resistance and other 
potential physiological alterations. 
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Materials and Methods 
Bacterial strains, media and growth conditions 
The strains Escherichia coli 3AG100 and BW25113 and derivatives were used in this study 
(Table 22). 
 
E. coli strains were cultured in Luria-Bertani (LB) broth or on LB agar plates at 37ºC. 
Antibiotics were added when necessary, at final concentrations listed in Table 16.  Liquid 
cultures were grown overnight in 14ml plastic tubes or erlenmeyer flasks. For E. coli 
strains carrying plasmids derived from pET6AP, IPTG was added in order to induce gene 
expression. 
 
In this work, we have used M. tuberculosis CDC1551 and derivatives (Table 23). All 
manipulations of M. tuberculosis were done in a Biosafety Level 3 Laboratory (BSL3).  
 
Liquid medium for M. tuberculosis was Middlebrook 7H9 medium supplemented with 10% 
OADC (0.05% oleic acid, 0.5% bovine serum albumin, 0.2% dextrose, 0.085% NaCl, 0.0003% 
beef catalase) (Difco) (7H9/OADC from now). In order to keep the culture clump-free, 
Tween 80 was added to a final concentration of 0.05%, except for the media used in 
susceptibility assays, which were supplemented with glycerol 0.5%. 
 
Solid medium was Middlebrook 7H10 or 7H11 medium supplemented with 10% OADC (Difco) 
(7H10/OADC from now).  
 
M. tuberculosis H37Rv was grown at 37ºc; liquid cultures were done in cell culture flasks, 
without shaking. 
 
Storage of strains was done in cryovials (MAST CRYOBANKTM). To prepare them, 2-3 colonies 
were taken from the agar plate and dispersed in the cryogenic preservative solution 
containing chemically treated beads. After 15 minutes of incubation at room temperature, 
the solution was removed and the vial containing the beads kept at -80ºC. 
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General techniques of nucleic acids 
Oligonucleotides 
All the oligonucleotides are listed in Tables 17 and 18. Artificial endonuclease restriction 
sites were added when required and are shown underlined. 
Oligonucleotides with cloning purposes 
Oligonucleotide Sequence 5’->3’ Description 
pET30-ORF6-Fw GAAGGAGATATACATATGAAAATCGAAG Sequencing pET6Ap derivatives 
MmpL7-Rv CAGCGTCCAAGAAAATACCG Sequencing pCVF7 
ctap3 CGCAGGTTCCAGACGAAG Sequencing pCVF1 
pET30-ORF6-Rv GCTTCCTTTCGGGCTTTG Sequencing pET6Ap derivatives 
p55-Fw GCGTTCTTCGGTTGGGAAC Sequencing pCVF2 
MmpL7-Fw1 GATCGTGCTGCTGACCGC Sequencing pCVF7 
MmpL7-Fw2 ATCGACACAGACAATGAGCG Sequencing pCVF7 
MmpL7-Rv2 CGTCCTGGATGGTTGTTTC Sequencing pCVF7 
P55- trans-in ACGCCCTGGCCGAACAGC Sequencing pCVF2 
MmpL7-30aORF6-F ATGCCTAGTCCGGCTGGC To clone mmpL7 gene in pET6Ap. 
Tap-pT7-7-F 
TTTTCATATGCGCAACAGCAACCGCGGCCCGG
CATTC 
To clone tap gene in pT7-7. NdeI site 
underlined.  
P55-pT7-7-F 
TTTTCATATGCGCGCGGGCCGCCGCGTGGCGA
TTAGCGCGGGCAGCCTG 
To clone P55 gene in pT7-7. NdeI site 
underlined.  
Tap-pT7-7-R TTTTAAGCTTATTCACTGAGCCGATCCT 
To clone tap gene in pT7-7. EcoRI site 
underlined 
P55-pT7-7-R TTTTAAGCTTGGTGGCTCGTTAGAGCGGCTCC 
To clone P55 gene in pT7-7. EcoRI site 
underlined 
pT7-7-Fw CATGTTTGACAGCTTATCATCGATG Sequencing pT7-7 derivatives 
pT7-7-Rv GGGAGACCACAACGGTTTC Sequencing pT7-7 derivatives 
MmpL7-30aORF6-R GTCTCGAACAGGCGGTCAAC To clone mmpL7 gene in pET6Ap. 
 
Compound E. coli M. tuberculosis 
Kanamycin (Km) 20 µg/ml 20 µg/ml 
Ampicilin (Ap) 100 µg/ml - 
Tetracyclin (Tet) 3 µg/ml - 
Streptomycin (Sm) 50 µg/lm - 
IPTG 1mM - 
Table 16. Antibiotics and compounds used in this work. 
 
 
Table 17. Oligonucleotides used in construction and verification of plasmids. 
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Oligonucleotides used for allelic exchange purposes 
Oligonucleotide Sequence 5’->3’ Description 
uppOlmmpL7 
TGCTCAGCCTGAACAGTCCAAGTCTTAACTT
AAACAGGAGCCGTTAAGACatgcctagtccg
gctggccgtcta 
To generate CVF13 strain. Used to 
amplify mmpL7 gene with homology arms 
(shown in capital letters), which are 
homologous to the 50 pb regions flanking 
acrB gene. 
 
lowOlmmpL7 
GTTATGCATAAAAAAGGCCGCTTACGCGGCC
TTAGTGATTACACGTTGTAtcaacgccgccc
tggcgtggtcgg 
repOlacrB615-
28mmpl 
GAACAACGTTGAGTCGGTGTTCGCCGTTAAC
GGCgccggggcaaggcaagcacagcaatacc
tcgatcccatgcTCGTTTCCTTGAAGGACTG
GGCCGATCGTCCGGGCG 
 
To generate CVF19 strain. Capital letters 
indicate the homology arms that hybridize 
within acrB gene. The region belonging to 
mmpL7 gene is shown underlined. 
acrB S 5-f CCTTCTTGCCAGATGAGGAC 
To confirm the replacement of the rpsL-
neo cassette by repOlacrB615-28mmpl 
oligonucleotide. Used to verify CVF19 
strain by sequencing. 
acrB S 5-r GCAGTACCCAGTTCCACGAT 
 
Plasmid DNA extraction (minipreparation) 
Plasmid DNA extractions were done with QIAprep Spin Miniprep Kit (Qiagen), following 
manufacter’s instructions. E. coli strains were cultured overnight either in LB liquid 
medium on LB agar plates; for extraction 1.5 ml liquid culture or culture from plate were 
used. 
Plasmidic DNA was kept at -20ºC. 
 
Construction of plasmids 
We used two expression vectors for E. coli: pT7-7 (70) and pET30a-ORF6 (43). 
Construction of vectors for expressing Rv1258c and Rv1410c efflux pumps from M. 
tuberculosis. 
The PCR amplifications for cloning were performed with a high fidelity DNA Polymerase 
(TripleMaster® PCR System (Eppendorf)). The oligonucleotides used in this PCRs were 
designed with the proper restriction sites. 
 
Table 18. Oligonucleotides used in allelic exchange techniques.  
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Since the codon usage in E. coli is different from the one of M. tuberculosis (7), we 
changed the first codons of Rv1258c and Rv1410c genes in order to optimise the expression 
of these mycobacterial efflux pumps in E. coli. With that aim, we designed primers with 
nucleotide substitutions so that they were adapted to the E. coli codon usage, and led to 
no change in the codified aminoacid (Fig 26). 
 
 
 
 
 
 
 
 
A 1279 pb fragment containing Rv1258c (tap) gene of H37Rv was amplified from pCRS4 
plasmid as a template (see Chapter 1), using oligonucleotides Tap-pT7-7-F and Tap-pT7-7-
R. PCR product was digested with enzymes NdeI and HindIII and ligated with the vector 
pT7-7 previously linearized with NdeI and HindIII, yielding the plasmid pCVF1. The plasmid 
was sequenced with the oligonucleotides pT7-7-Fw, pT7-7-Rv and ctap3 (Table 17) to 
confirm the insert. 
 
In order to generate pCVF2, a 1583 bp fragment containing Rv1410c (P55) gene from M. 
tuberculosis H37Rv was amplified by PCR from pCVZ1 (see chapter 1) with oligonucleotides 
P55-pT7-7-F and P55-pT7-7-R. This PCR fragment was digested with the restriction 
enzymes NdeI and HindIII and inserted into pT7-7 vector digested with NdeI and HindIII. 
The resulting plasmid was sequenced with oligonucleotides pT7-7-Fw, pT7-7-Rv, P55-Fw 
and P55-trans-in to verify the insert (Table 17). 
A. Rv1258c 
B. Rv1410c 
Fig. 26. Forward primers for amplification of Rv1258c and Rv1410c genes adapted to codon usage of E. 
coli. Nucleotide substitutions are highlighted in yellow. The recognition site for NdeI restriction enzyme is 
written in blue and underlined. 
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Construction of vectors for expressing MmpL7 efflux pump from M. tuberculosis 
We generated a bicistronic plasmid that didn’t carry a kmR gene, so it could be used for 
expression of mycobacterial genes in Km-resistant E. coli strains. First, the Ω-Ap cassette, 
was released from plasmid pKT254Ω-Ap (34) by digestion with SmaI restriction enzyme, 
and subsequently inserted in the SmaI site of the KmR gene in pET30a-ORF6 (43). The 
resulting plasmid, pET6Ap, was checked by restriction analysis with SmaI. The orientation 
of the Ω-Ap cassette was not investigated. 
 
In order to construct pCVF7, a 7841 bp fragment containing mmpL7 gene from H37Rv was 
amplified using oligonucleotides MmpL7-30aORF6-F and MmpL7-30aORF6-R, with Phusion 
High-Fidelity DNA Polymerase (New England Biolabs), which leaves the product with blunt 
ends. As a template, BAC-Rv30 (which contains from 3281413-3356541 nucleotides from 
H37Rv genome) was used. The plasmid pET6Ap was linearized with EcoRV, yielding a blunt-
ended fragment, and subsequently ligated with the insert. To select the correct 
orientation of the insert in the resulting plasmid, two PCRs were performed: i) pET30-
Fig. 27. pT7-7 vector and derived plasmids pCVF1 and pCVF2  
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ORF6-Fw and MmpL7-Rv , ii) pET30-ORF6-Rv vs MmpL7-Fw2 (Table 17). The plasmid was 
then sequenced with pET30-ORF6-Fw, pET30-ORF6-Rv, MmpL7-Fw1, MmpL7-Fw2, MmpL7-
Rv and MmpL7-Rv2 (Table 17), to confirm the absence of mutations in the insert. 
 
 
 
Plasmids 
Plasmid Marker genes Description Ref. 
pT7-7 Ap 
Vector for expressing genes under control of T7-
promoter in E. coli. 
(70) 
pCVF1 Ap 
pT7-7 derived plasmid with Rv1258c (tap) gene, 
under control of T7 promoter. 
This 
work 
pCVF2 Ap 
pT7-7 derived plasmid with Rv1410c (P55) gene 
under control of T7 promoter. 
This 
work 
pET30a-
ORF6 
Km (Tn903- derived) 
Vector for expressing genes under control of T7-
promoter in E. coli, upon induction with IPTG. 
(43) 
pET6Ap Ap 
Derived from pET30a-ORF6, with KmR inactivated 
by insertion of Ω-ApR cassette. 
This 
work 
pCVF7 Ap 
pET6Ap derived plasmid with mmpL7 gene under 
control of T7 promoter, upon induction with IPTG. 
This 
work 
 
Fig 28. A. pET6Ap, derived from pET30a-ORF6, the KmR gene is inactivated by the Ω-ApR cassette 
(orientation is not known). B. pCVF7 plasmid, for expression of mmpL7. 
Table 19. Plasmids used in this study 
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Generation of E. coli competent cells & electroporation  
To prepare electrocompetent cells, 150 ml of a bacterial culture were grown to an OD600nm 
of 0.4. Then the growth was stopped for 30 min on ice, and bacteria were washed twice in 
chilled-cold water, and once in chilled-cold 10% glycerol. Cells were finally resuspended in 
1 ml chilled-cold 10% glycerol. Aliquots of 40 µl can be storaged at -80ºC for further use. 
 
Alternatively, if cells are to be electroporated inmediately, a simplified protocol can be 
used. Independent aliquots of 1.4 ml LB, pre-warmed at 37ºC, were inoculated with 30 µl 
fresh E. coli culture, and incubated at 37ºC 1000 rpm until they reached an OD~0.4. 
Growth was then stopped by placing the cells on ice for 2 minutes. Subsequently, bacteria 
were pelleted (11000 rpm, 30s, 2ºC) and two washes with 1ml chilled-cold water were 
performed. Finally, the pellet was resuspended in 30-40 µl chilled-cold water and 
immediately electroporated. 
Electroporation 
Aliquots of 40 µl were electroporated with 1 µl purified plasmid (~100 ng) DNA in 0.1 cm 
gap cuvettes (Bio-Rad) with a single pulse (1,8 kV) in a E. coli PulserTM (Bio-Rad). Cells 
were resuspended in LB to a final volume of 1 ml and incubated for 1h at 37ºC 1000 rpm 
before plating several dilutions on plates containing the needed antiobiotic. Colonies 
appeared after incubation overnight. 
 
Construction of mutants by Allelic Exchange in E. coli 
These method is based in the enhanced recombination frequency by external recombinase 
enzymes, belonging to λ-phage. We used the Counter Selection BAC Modification Kit (Gene 
Bridges). This kit contains the plasmid pRedET, which carries the λ-phage redγβα operon 
expressed under the control of the arabinose-inducible pBAD promoter, it has a 
thermosensitive origin of replication and confers tetracycline resistance.  
 
The homologous recombination event will take place between a targeted gene of the 
bacterial chromosome (acrB gene in this case) and a linear DNA fragment flanked by two 
homology arms. Each homology arm is 50 bp long, and they will determine the region 
where the homologous recombination will occur. In a first step of recombination, a rpsL-
neo cassette, conferring resistance to Km and susceptibility to Sm, flanked by these 
homology arms, is inserted. The final construction is obtained by recombination of a DNA 
linear fragment that replace the rpsL-neo cassette. 
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This fragment was obtained by PCR, using a high fidelity DNA Polymerase (TripleMaster® 
PCR System (Eppendorf)) and oligonucleotides designed with the correspondent homology 
arms (Table 18). Subsequently, this PCR product was precipitated with 3 volumes of EtOH 
and 0,1 volumes of NaAc 3M, incubated at -80ºC for 5 min and then pelleted and 
resuspended to a final concentration 0,5-1 µg/ml.  
 
 
 
The rpsL-neo cassette had been previously introduced into the acrB gene of strain 3AG100 
(20). First, pRedET was transformed in the selected E. coli strain. All the incubations must 
be done at 30ºC in order to keep this themosensitive plasmid. The next step was the 
electroporation of the linear DNA fragment. For this, 30 µl of culture grown at 30ºC 
overnight were used to inoculate an aliquot of 1.4 ml LB/Tet broth. When this culture 
reached OD600nm=0.2-0.3, 50 µl L- arabinose 10% were added, and further grown at 37ºC in 
order to induce the expression of recombinases, until OD600nm=0.4. Growth was then 
stopped by placing the cells on ice for 2 minutes. Subsequently, bacteria were pelleted 
(11000 rpm, 30s, 2ºC) and two washes with 1ml chilled-cold water were performed. 
Finally, the pellet was resuspended in 30-40 µl chilled-cold water and immediately 
electroporated with 1 µl purified plasmid (0,5-1 µg DNA) in 0.1 cm gap cuvettes (Bio-Rad) 
with a single pulse (1,8 kV) in a E. coli PulserTM (Bio-Rad). Cells were resuspended in LB to 
a final volume of 1 ml and incubated for 1h at 37ºC 1000 rpm. The strains resulting from 
the homologous recombination have lost the rpsL-neo cassette, thus they are Km 
susceptible and Sm resistant; because of this the transformation mix was plated on LB Sm 
and incubated at 37ºC overnight. The thermosensitive plasmid pRedET was eliminated by 
incubating at 37ºC. Several PCRs were performed in order to verify the generated strains. 
Reagents & solutions 
NaAc: NaAc 3M pH 5,3  
 
Fig.29. Schematic representation of the allelic exchange replacement for generating mutants of E. coli. 
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Susceptibility assays 
E. coli 
Serial two-fold dilutions of antibiotics were performed in LB medium in 96-well microtiter 
plates, with a final volumen of 50µl per well. Cultures grown overnight on agar LB plates 
were used to prepare a cell suspension in NaCl 0,9%, and turbidity was adjusted to 0.5 
McFarland standard. This suspension was diluted 1/50 and use to inoculate the antibiotic 
plate, with a volumen of 50 µl per well. Results were observed after 15-18h of incubation 
at 37ºC. Minimal Inhibitory Concentration (MIC) was the one of the first well with no visible 
bacterial growth. 
 
M. tuberculosis 
Serial two-fold dilutions of antibiotics were performed in 7H9/glycerol 0.5%/OADC 
medium, in 96-well microtiter plates, with a final volumen of 100µl per well. Liquid 
cultures in logarithmic phase were adjusted to OD600nm ~ 0.25 and diluted 1/100 in 
7H9/glycerol 0.5%/OADC. 100µl of this suspension were added to each well and plates 
were incubated 6 days at 37ºC. 30 µl of a resazurin solution 0,1 mg/ml were added to each 
well, and results were observed after 48h of incubation at 37ºC. Resazurin (blue) is an 
indicator of bacterial growth, because metabolic activity of bacteria reduces it to 
resofurin (pink). Minimun Inhibitory Concentration (MIC) is the concentration of antibiotic 
of the first well that doesn’t change color from blue to pink. 
Solutions & Reagents 
Resazurin: 0,1 mg/ml resazurin in distilled water 
 
Accumulation assays 
We performed acummulation assays with ethidium bromide (EtBr) (18, 71), phenyl-
arginine-ß-naphthylamide (PAßN) (19) and pyronin Y (Pyr) (89), in presence and absence 
of efflux inhibitors, such as carbonyl cyanide m-chlorophenylhydrazone (CCCP), PAßN 
and 1-(1-naphthylmethyl)-piperazine (NMP).  
 
The intracellular accumulation of these compounds was estimated by measuring 
fluorescence intensity. Each compound tested has different characteristics that make them 
suitable for this assay: EtBr increases its fluorescence when its intercalated in the DNA; 
PAßN is cleaved by intracellular esterases to yield the highly fluorescent metabolite ß-
naphthylamine; and fluorescence of Pyr is quenched after binding to RNA. 
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An overnight culture on agar LB plate was used to make a suspension in buffer (PBS 1x + 
0,4% glucose). O.D. 600nm was adjusted to 1 and 200 µl of this suspension transferred to 
each well of a opaque black 96-well plate. 
 
The substrate of accumulation was then added to the cell suspension to the 
corresponding final concentration (EtBr 25µM, PAßN 200µM, Pyr 2,5µM) and, if 
necessary, the efflux inhibitor to a final concentration of 200µM. Wild-type and ∆acrB 
strains were included as controls.  
 
Relative fluorescence intensity was measured over time in a Safire (Tecan, Crailsheim, 
Germany) fluorescence plate-reader. Selected wavelengths for measuring each compound 
are listed in Table 20. 
 
  
 
 
 
Real-time accumulation and efflux assays 
First, we prepared a bacterial suspension to perform these assays. For this, a 20 ml LB 
medium was inoculated directly from cryovials of from an overnight culture on agar LB 
plates. This culture was incubated overnight (18-20h) at 37ºC and shaking (200 rpm), thus 
it will reach stationary phase and starvation of nutrients. 10 ml of this stationary culture 
were transferred to a 50ml tube and washed with 20 ml PPB buffer (20mM K3PO4, 1 mM 
MgCl2, pH7). Then, it was centrifuged (5 min at 4000rpm), supernatant removed and pellet 
resuspended in 30ml of PPB buffer. With the same buffer it was adjusted to an OD600= 0.25. 
This cell suspension was used to perform two different experiments: 
 
a) Real time efflux assay 
b) Real time accumulation & efflux assay 
 
These assays must be performed with AcrAB-TolC substrates fulfilling a very important 
characteristic: they must be strongly fluorescent in a non-polar environment, and its 
fluorescence decreased drastically in a polar environment. Because of this, we are able to 
distinguish the compound inside the bacteria from the one outside. In our study, we used 
Compound λ. Excitation Max. (nm) λ Emission Max (nm) 
EtBr 518 605 
PAßN 320 460 
Pyr 545 570 
Table 20. Wavelength settings for compounds used in accumulation 
assays. 
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1,2-Dinaphthylamine (1,2-DNA) (21) and BM-27; both are highly lipophilic and consequently 
they adhere to plastic, because of this all the tubes must be made of glass. 
Real time efflux assay 
2 ml of bacterial suspension previously prepared were transferred to a glass tube, CCCP 
added to a final concentration of 5-20 µM (depending on the E. coli strain) and incubated 
for 15 minutes to de-energize the cells. 1,2’-DNA was added to a final concentration of 16 
µM; it enters the cell by passive difussion, but the bacterium is not able to export it by 
active efflux, thus resulting in the accumulation inside the cell. The glass tube was sealed 
with film and incubated 2-3 h at room temperature. As a result, bacteria were loaded with 
1,2’-DNA. 
 
When the incubation time was over, CCCP and 1,2’-DNA that didn’t enter into bacteria 
were removed by washing the pelleted bacteria with 2 ml of PPB. This suspension was 
transferred to a quarzt cuvette and placed into a spectrofluorometer (Perkin Elmer LS55). 
By measuring the fluorescence we were informed of the efflux of the substrate in real 
time.  
 
At second 100 of experiment, pre-loaded bacteria were stimulated with glucose at a final 
concentration of 50 mM. Glucose energizes the cells, which are now able to actively export 
the substrate through their transporters. This phenomenon was translated into a decrease 
of fluorescence. 
 
Real-time accumulation and efflux assay 
 
2 ml of the cell suspension were transferred to a quartz cuvette and inmediately placed in 
the spectrofluorimeter to start measurement. After 50 s, CCCP was added to a final 
concentration of 10 µM; due to quenching effect, fluorescence signal was reduced. At 500 s 
from the start of the experiment, BM-27 was added to a final concentration of 10 µM and 
as a consequence of accumulation inside the bacteria, fluorescence started to raise. At 
second 1000, glucose was added to a final concentration of 50 mM in order to energize the 
cells; in response a fluorescence decrease was observed, as a consequence of the active 
efflux of BM-27.  
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Phenotypical characterisation of M. tuberculosis 
Growth in liquid medium 
In order to characterize growth in liquid medium, 1ml of a culture in logarithmic phase 
adjusted to OD600=0.25 was inoculated in 50 ml of 7H9/Tween/OADC. OD600 was measured 
for 1 month. When OD600 reached 1, the culture was diluted ½ and ¼ and OD corrected 
atending the dilution. In addition, on days 4, 8 and 16 of growth, serial dilutions were 
plated to find the number of viable bacteria corresponding to each OD measurement. 
Morphology of colonies was evaluated at 2-4 weeks of growth on solid medium. 
 
Ziehl-Neelsen Stain 
250 µl of liquid culture in logarithmic phase were pelleted, and mycobacteria inactivated 
with 350 µl paraformaldehyde 4% for 30-35 min at room temperature. They were washed 
with 150 µl PBS + tween 0,05% and staining was performed as described in literature (6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dye λ. Excitation Max. (nm) λ Emission Max 
(nm) 
λ 2nd Excitation Max (nm) 
1,2’-DNA 370 460 810 
BM-27 400 457 873 
Table 21. Wavelength settings for dyes used in real time efflux and accumulation 
assays. 
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Escherichia coli strains 
Derived from 3AG100 
Resistance 
marker 
Description Ref. 
3AG100 - 
AG100 derived strain overexpressing acrB 
gene  
(47) 
3AG100 ∆acrB (St. 320) km 3AG100 acrB::rpsLneo 615-628 (20) 
3AG100 ∆acrB (St. 513) km 3AG100 acrB::rpsLneo (20) 
3AG100 ∆acrB (St. 540) none 3AG100 ∆acrB (20) 
CVF13 Ap 3AG100 acrB::mmpL7 This work 
CFV19 Ap 3AG100 acrB615-28::mmpL7 535-48 This work 
Derived from BW25113 Resistance marker Description Ref. 
BW25113 (wild type) - Wild type strain (97) 
ΔacrB - BW25113 ∆acrB (97) 
∆emrE - BW25113 ∆emrE (97) 
∆mdfA km BW25113 ∆mdfA:: km (97) 
ΔacrBΔemrE - BW25113 ∆acrB ∆emrE (97) 
ΔemrEΔmdfA km BW25113 ∆emrE ∆mdfA::km (97) 
ΔacrBΔemrEΔmdfA km BW25113 ∆acrB ∆emrE ∆mdA::km (97) 
Δsmr - BW25113 ∆emrE ∆mdtIJ ∆sugE (97) 
CVF1 Ap BW25113 pT7-7 This work 
CVF2 Ap BW25113 pCVF1 This work 
CVF3 Ap, Km ΔemrEΔmdfA pCVF1 This work 
CVF4 Ap, Km ΔacrBΔemrEΔmdfA pCVF1 This work 
CVF5 Ap, Km ΔmdfA pCVF1 This work 
CVF6 Ap, Km ΔmdfA pCVF2 This work 
CVF7 Ap ΔemrE pCVF1 This work 
CVF8 Ap ΔemrE pCVF2 This work 
CVF9 Ap, Km ΔemrEΔmdfA pCVF2 This work 
CVF10 Ap ΔacrB pCVF1 This work 
CVF11 Ap ΔacrB pCVF2 This work 
CVF12 Ap ΔacrBΔemrEΔmdfA pCVF2 This work 
CVF14 Ap ΔacrB pT6Ap This work 
CVF15 Ap ΔacrB pCVF7 This work 
 
Mycobacterium tuberculosis strains 
Derived from CDC1551 Resistance marker Description 
CDC1551 - Wild type strain 
MmpL7KO Km CDC1551 ∆mmpL7::km 
MmpL10KO Km CDC1551 ∆mmpL10::km 
Table 23. M. tuberculosis strains used in this study 
 
Table 22. E. coli strains used in this study 
 
  
 
 
133 
Results 
Expression of efflux pumps from M. tuberculosis in E. coli 
Two strains of E. coli were used: BW25113 and 3AG100, both derived from E. coli K-12. 
3AG100 is a strain generated by repeated exposure of AG100 to a fluoroquinolone (47), and 
it overexpresses AcrAB-TolC efflux pump. Knock-out mutants ∆mdfA, ∆emrE and 
∆mdfA∆emrE were available for E. coli BW25113 (97). The knock-out mutant ∆acrB was 
available for BW25113 and 3AG100 (20, 97). 
 
There are morphological differences between BW25113 and 3AG100; the first one forms 
bigger colonies. It has been described that BW25113 is more resistant to ethidium bromide 
than most of the E. coli strains (97). Consistenly, in our study we have found that bigger 
concentrations of efflux inhibitors are requiered to de-energize bacteria in the case of 
BW25113. 
 
Generation of E. coli strains containing M. tuberculosis efflux pumps genes in 
expression vectors for E. coli. 
 
In order to generate E. coli strains expressing efflux pumps from mycobacteria, plasmids 
pCVF1 and pCVF2 were transformed by electroporation in E. coli strains: BW25113 ∆mdfA, 
BW25113 ∆emrE and BW25113 ∆mdfA ∆emrE. pCVF7 was transformed in E. coli BW25113 
∆acrB and 3AG100 ∆acrB.  (Table 22) 
 
Generation of E. coli strains containing complete or partial M. tuberculosis efflux 
pumps genes in its chromosome. 
 
Allelic replacement was used to generate E. coli strains containing either the whole or part 
of the gene mmpL7 in its chromosome. The first step of the process, the insertion of rpsL-
neo in the targeted region, had been made previously (20).  
 
In order to obtain CVF13, a 3AG100-derived strain with the gene mmpL7 from M. 
tuberculosis H37Rv replacing acrB, a 2863 bp fragment was amplified from M. tuberculosis 
H37Rv DNA with oligonucleotides uppOlmmpL7 and lowOlmmpL7. This DNA linear fragment 
was electroporated in 3AG100 ∆acrB (St.513) (table 22) containing pRedET plasmid, after 
induction of the recombinases. Colonies with phenotype Sm resistant and Km sensitive 
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were selected. The presence of mmpL7 gene was checked by PCR with oligonucleotides 
mmpL7-Fw1 and mmpL7-Rv2, which yields a 1235 pb fragment. 
 
The same method was used to create a hybrid acrB-mmpL7 gene. The susbtrate binding 
site of AcrB has been described previously (20), and our aim was to replace a key region of 
its binding site by the hypothetically analogous region of MmpL7. This region comprised 
aminoacids 615-628 of AcrB, and was substituted by aminoacids 535-548 of MmpL7 protein. 
The objective of this hybrid mutant was to discover if, when part of the substrate binding 
site was replaced by the one of MmpL7, the pump was still functional and, if so, the 
substrate profile transported was different. In this case, since the region to be replaced 
was small, the linear DNA fragment was not a PCR product, but a 110 bp oligonucleotide, 
repOlacrB615-28mmpl (Table 18). This was transformed in the 3AG100 ∆acrB (St. 320) 
strain containing pRedET plasmid, as described. Colonies with phenotype Sm resistant and 
Km sensitive were selected. The replacement of the rpsL-neo cassette was verified by PCR 
and further sequenced with the same pair of oligonucleotides (Table 24). The resulting 
strain was called CVF19. 
 PCR product size 
Oligonucleotides 3AG100 ∆acrb (St. 320) CVF19 
acrB S 5-f vs. acrB S 5-r 1625 bp 346 bp 
 
 
 
Susceptibility assays of E. coli strains with M. tuberculosis efflux pumps genes 
One of our main objectives was to find if certain efflux pumps from M. tuberculosis can be 
expressed and functional in E. coli. With that aim, we compared levels of antibiotic 
resistance of E. coli strains with efflux pumps genes deleted, with and without a vector 
containing an efflux pump gene from M. tuberculosis.  
 
 
 
 
 
 
 
 
 
Table 24. Verification by PCR of CVF19 strain, containing a hybrid acrB::mmpL7 gene 
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No significant differences were observed in the MICs of the “complemented” mutants, nor 
in the case of MFS proteins neither in RND transporters. One of the possible explanations 
for this fact is that efflux pumps are not being correctly expressed from expression 
vectors. That is the reason why we constructed another expression strain for MmpL7, this 
time replacing the acrB gene by mmpL7 gene in the chromosome of E. coli 3AG100. 
Resistance profile of this new strain was coincident with the one of the knockout mutant 
∆acrB. 
 
Finally, a hybrid gene acrB-mmpL7 was generated. This gene consisted of the entire acrB 
gene, replaced only in a small but very important region belonging to the substrate binding 
site. This region was changed by the hypothetically homologous region of MmpL7 
transporter, that was located by alignment of the aminoacidic sequences. The hybrid 
mutant showed the same MICs than the knock-out mutant ∆acrB, thus we inferred that the 
hybrid proteins was not functional, or it wasn’t being expressed by the bacteria. 
 
Accumulation assays 
As a result of the “complementation” of the knock-out mutants of E. coli with efflux 
pumps from M. tuberculosis, we would expect that, if those transporters were functional, 
the accumulation was lower for them than for the knock-out mutant.  
 
In none of the cases, neither for MFS nor RND proteins, we found the expected result, 
because the generated strains behaved the same way as the knock-out mutant. It must be 
noted that, for the E. coli strains expressing Rv1258c from M. tuberculosis, we found a 
difference in the accumulation of PAßN in presence of the efflux inhibitor NMP, but this 
was a raise in the accumulation, not a reduction.  
 
Rifampicin Rifaximin 
Streptomycin Spectinomycin 
Gentamicin Tetracycline 
Minoclycine Tigecycline 
Levofloxacin Moxifloxacin 
Ciprofloxacin Clarithromycin 
Erythromycin Clindamycin 
Chloramphenicol Linezolid 
Novobiocin  
Table 25. Antibiotics tested in susceptibility assays of E. coli strains. 
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Accumulation assays for EtBr and PAßN revealed that 3AG100 strain has a higher level of 
accumulation that BW25113, both for PAßN and EtBr.  
 
Real time efflux and accumulation 
In the host laboratory, real time efflux and accumulation assays were optimized for E. coli 
3AG100, so the first step was to set the best conditions for the strain BW25113. Regarding 
real time accumulation and efflux, an increase in CCCP concentrations (from 5 µM to 20 
µM) was necessary to improve accumulation; however, this accumulation didn’t reach the 
levels of the one in 3AG100. In order to allow a better accumulation, longer times of 
exposition to CCCP were tried, unsuccessfully. In addition, BW25113 ∆acrB and 
∆acrB∆mdfA∆emrE showed lower efflux levels than the wild type (Fig. 30 and 31), but still 
significant when compared to 3AG100 ∆acrB knock-out mutant. 
 
 
Given the small or even no differences in efflux between BW25113 and its knock-out 
mutants, we concluded that it wouldn’t have been possible to detect changes in the 
phenotype of the “complemented” knock-out mutants of E. coli BW25113. 
 
The strain CVF13 (3AG100 acrB::mmpL7) was compared to the wild-type strain 3AG100 and 
3AG100 ∆acrB. In both experiments, CVF13 has the same behaviour that ∆acrB (Fig 32 and 
Fig 33), so that we deduced that MmpL7 efflux pump was not being correctly expressed, or 
1,2’-DNA and BM-27 are not substrates of the efflux pump. 
 
Fig.30. Real time efflux of 1,2-DNA of BW25113 
and BW25113 ∆acrB. 
Fig.31. Real time accumulation and efflux of BM-
27 of BW25113 and BW25113 ∆acrB. 
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Characterization of mutants MmpL7KO and MmpL10KO of M. tuberculosis 
 
MmpL7KO has less growth rate and forms less aggregates in liquid medium 
MmpL7KO mutant showed phenotypical differences when compared to wild-type strain 
CDC1551. Firstly, MmpL7KO has an increased rate of growth in liquid medium, regarding 
both to OD measurement and counts of viable bacteria. At day 8 of growth, OD of the 
cultures of wild-type and MmpL7KO started to diverge, and from day 15 differences 
became more obvious. On the other hand, MmpLKO grew at similar rate as the wild-type, 
but slightly faster. Differences between them are clearer in the count of viable bacteria 
(Fig 34) 
 
 
 
 
Fig. 32. Real time efflux of 1,2’-DNA 
of 3AG100 wild type and 3AG100 
acrB::mmpL7 in the presence and 
absence of the inhibitor NMP. 
Fig. 33. Real time accumulation 
and efflux of 1,2’-DNA of 3AG100 
wild type and 3AG100 
acrB::mmpL7.. 
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In addition, liquid culture of MmpL7KO forms less aggregates than the one of the wild-type 
strain, like it is showed in Fig. 35.  
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Fig.34. Characterisation of growth rates in liquid medium of CDC1551, MmpL7KO and MmpL10KO, by OD 
measurements and cfu count. 
Fig 35. A. Liquid cultures of CDC1551, MmpL7KO and MmpL10KO. MmpL7KO forms less aggregates than the wild 
type strain. B. Sediment of liquid cultures of CDC1551 (n.1), MmpL7KO (n.3) and MmpL10KO (n.2). after 
resuspending and let them stand for about five minutes. 
A B 
  
 
 
139 
Zielh-Neelsen Staining 
Microscope visualization of stainings did not reveal significant differences in the 
morphology of wild-type and mutants bacilli (Fig. 36). 
                           
 
 
 
Antibiotic susceptibility of MmpL7KO and MmpL10KO 
With the aim of studying the posible contribution of MmpL7 and MmpL10 efflux pumps to 
intrinsic resistance of M. tuberculosis, we determined the MIC of MmpL7KO, MmpL10KO 
and CDC1551 to several compounds, including first and second line antituberculosis 
antibiotics. 
 
Both mutants seemed to be more susceptible (two-fold) to tetracycline and spectinomycin, 
when compared to the wild-type strain. In addition, MmpL7KO showed more susceptibility 
to rifampicin and MmpL10KO could contribute to resistance to minoclycin. (Table 26) 
 
 
 
 
 
 
 
 
 
 
 
 
 
CDC1551 MmpL7KO MmpL10KO 
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Compound CDC1551 MmpL10KO MmpL7KO 
Isoniazid 0,05-0,1 0,05-0,1 0,05-0,1 
Rifampicin 0,125-0,250 0,125-0,250 0,0625 
Rifaximin <0,0625 <0,0625 <0,0625 
Ethambutol 1 1 1-2 
Streptomycin 0,125-0,25 0,25 0,125-0,25 
Spectinomycin 64-128 32-64 32-64 
Gentamicin 2 2 2 
Tetracycline 8 4 4 
Minocycline 2-4 1-2 2 
Tigecycline 2-4 2-4 2-4 
Levofloxacin 0,25 0,25 0,25 
Moxifloxacin 0,125 0,125 0,0625-0,125 
Ciprofloxacin 0,25-0,5 0,25 0,25-0,5 
Clarithromycin 2 2 2 
Erythromycin 256 256 256 
Clindamycin 32-64 32-64 32-64 
Chloramphenicol 2-4 4 2-4 
Linezolid 0,25 0,25 0,25 
Novobiocin 32 32 32 
Acriflavine 2 2 2 
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CONCLUSIONS 
 
• Plasmids for expressing Rv1258c and Rv1410c (MFS) efflux pumps and MmpL7 (RND) 
from M. tuberculosis have been constructed. 
 
• E. coli strains containing either the whole mmpL7 gene from M. tuberculosis or a 
hybrid gene acrB:mmpL7 have been generated. 
 
• No clear evidence of expression of mycobacterial efflux pumps in E. coli was found. 
 
• MmpL7 knock-out mutant of M. tuberculosis efflux pump has an apparently 
increased growth rate in liquid medium, and displayed altered colony morphology.  
 
• Knock-out mutants of mmpL7 and mmpL10 seemed to be more susceptible to 
tetracycline and spectinomycin, when compared to the wild-type strain. MmpL7KO 
showed more susceptibility to rifampicin and MmpL10KO could contribute to 
resistance to minoclycin. 
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Conclusiones generales 
- La bomba de eflujo Rv1258c (Tap) de M. tuberculosis está implicada en resistencia 
intrínseca a estreptomicina, gentamicina y espectinomicina. El mutante knock-out de 
Tap no mostró diferencias en la susceptibilidad a tetraciclina comparada con la del 
wild-type H37Rv, como sí ocurría con el mutante análogo en M. bovis BCG. Los 
experimentos de infección de macrófago de ratón revelaron que Tap puede tener un 
papel en la virulencia de M. tuberculosis; sin embargo, en el modelo de infección de 
ratón inmunocompetente no se observaron diferencias entre el knock-out de Tap y la 
cepa wild type H37Rv. 
 
- La bomba de eflujo Rv1410c (P55) de M. tuberculosis contribuye a la resistencia 
intrínseca a rifampicina, uno de los dos principales fármacos anti-tuberculosos, y a 
vancomicina. El mutante knock-out de P55 presenta alteraciones en el crecimiento en 
medio sólido: crece más despacio que la cepa wild-type, y la morfología de colonia es 
más plana y lisa. Los experimentos de infección de modelo celular de macrófago de 
ratón e in vivo, con ratones inmunocompetentes, mostrarons que P55 es necesaria 
para la virulencia completa de M. tuberculosis. 
 
- El mutante knock-out de Rv2333c (Stp)  no mostró diferencias en la sensibilidad a 
tetraciclina y espectinomicina, como sí ocurría con su análogo en M. bovis BCG, en 
comparación con la cepa wild-type. Atendiendo a los ensayos de infección en modelo 
de macrófago de ratón, se observó que Rv2333c podría contribuir a la virulencia de M. 
tuberculosis. sin embargo, en el modelo de infección de ratón inmunocompetente no 
se observaron diferencias entre el knock-out de Stp y la cepa wild type H37Rv. 
 
- Rv1258c, Rv2333c y Rv1410c no parecen estar implicadas en la inducción de apoptosis 
de las células macrófago de ratón. 
 
- Las cepas de la familia Beijing tienen una inserción (llamada Tap580) de un nucleótido 
de citosina entre las posiciones 580 y 581 del gen Rv1258c. Esto resulta en una 
proteína hipotéticamente truncada. Un método PCR-RFLP que detecta esta inserción 
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se ha puesto a punto; permite la detección de cepas de la familia Beijing incluso 
desde muestras clínicas de esputo.  
 
- Varias estrategias de expresión de bombas de eflujo micobacterianas en E. coli se 
llevaron a cabo. No se encontraron evidencias claras de expresión de estas proteínas. 
 
- El mutante knock-out de MmpL7 tiene una velocidad de crecimiento mayor que la 
cepa wild-type, así como una morfología de colonia alterada. 
 
- Aunque las diferencias en la sensibilidad fueron pequeñas, tanto el mutante knock-
out de MmpL7 como el de MmpL10 resultaron ser más sensibles a tetraciclina y 
espectinomicina, comparando con la cepa wild-type. Además, MmpL7KO mostró 
mayor sensibilidad a rifampicina, mientras que MmpL10 podría estar contribuyendo a 
la resistencia intrínseca a minoclicina. 
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General Conclusions 
- The efflux pump Rv1258c (Tap) of M. tuberculosis is implicated in intrinsic 
resistance to streptomycin, gentamicin and spectinomycin. The knock out mutant 
of tap didn’t show a difference in susceptibility to tetraclycine compared to the 
wild type H37Rv strain, as it did with M. bovis BCG model. Infection assays in 
mouse macrophage cell model revealed that Tap could have a role in virulence. 
However, the knock-out mutant of Rv1258c had the same phenotype as H37Rv in 
infection assays in immunocompetent mouse model.  
 
- Rv1410c (P55) efflux pump of M. tuberculosis is contributing to intrinsic 
resistance to rifampicin, one of the two main antibiotics in antituberculous 
treatment, and vancomycin. H37Rv knock-out mutant of Rv1410c has altered 
growth in solid media: it grew more slowly than the wild-type and showed a 
flatter and smoother morphology of colony. Mouse macrophage cell infection 
assays and in vivo infection (immunocompetente mice) showed that P55 has a 
role in virulence of M. tuberculosis. 
 
- H37Rv knock-out mutant of Rv2333c (Stp) didn’t show increased susceptibility to 
tetracycline and spectinomycin, as it did M. bovis BCG Rv2333c knock-out 
mutant. Infection assays in mouse macrophage cell model revealed that Stp could 
have a role in virulence. However, infection assays of immunocompetent mice 
showed no difference between the replication in lungs of the knock-out mutant 
of Rv2333c and that of H37Rv wild-type strain. 
 
- Rv1258c, Rv2333c and Rv1410c don’t seem to be implicated in apoptosis 
induction of mouse macrophage cells. 
 
- Beijing strains carry a insertion of a cytosine nucleotide between positions 580 
and 581 (called Tap580) of Rv1258c gene. This results in a hypothetically 
truncated Tap protein. A PCR-RFLP method that detects Tap580 insertion has been 
developed. It allows fast detection of Beijing strains even from sputum samples. 
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- Several strategies to express mycobacterial efflux pumps in E. coli had been 
made. No clear evidence of expression of these efflux pump was found. 
 
- MmpL7 knock-out mutant of M. tuberculosis efflux pump has an apparently 
increased growth rate in liquid medium, and displayed altered colony 
morphology.  
 
- Although differences in susceptibility are small, knock-out mutants of mmpL7 and 
mmpL10 seemed to be more susceptible to tetracycline and spectinomycin, when 
compared to the wild-type strain. MmpL7KO showed more susceptibility to 
rifampicin and MmpL10KO could contribute to resistance to minoclycin. 
 
 
